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Abstract 
 
Queuine is a modified nucleotide known to occur in the anticodon of four tRNAs.  
The queuine modification occurs across all eukaryotes and eubacteria with few 
exceptions, but its function remains unclear.  Prior in vitro work demonstrated that the 
modification can be incorporated into RNA species other than presently known tRNAs.  
Queuine is unusual in that, unlike the majority of modified nucleotides that result from 
changes to genetically encoded bases, it is incorporated into RNA by transglycosylation.  
Base modification by transglycosylation is unusual and represents an interesting point of 
entry for study.  Due to this method of incorporation the modification can be studied 
with small molecule probes.  Tritium-labeled queuine and preQ1 were prepared to study 
the differences between the eukaryotic and eubacterial version of the enzyme 
responsible for the incorporation of the modified base, tRNA guanine transglycosylase.  
A concise, convergent synthesis of queuine was developed that is the shortest known 
route to date.   
PreQ1, the precursor to queuine incorporated by eubacteria, was used to 
investigate the prevalence of base modification in E. coli.  Three cell lines were utilized 
to conduct the in vivo experiments of this study: a ΔqueC knockout of E. coli that is 
unable to synthesize preQ1 so that tritium labeled compound will be incorporated 
exclusively, a Δtgt knockout strain of E. coli that is unable to incorporate preQ1 and a 
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wild-type E. coli strain.  As the modified nucleotide occurs through incorporation of a 
specially synthesized nucleotide, a study of the sites of modification by prepared probes 
is possible.  The syntheses of two novel azide congeners were undertaken for this 
purpose.  The evaluation of their interaction with tRNA guanine transglycosylase was 
undertaken to determine if they are substrates of the enzyme.   
 The tritium labeled preQ1 allowed for a general evaluation of the prevalence.  
We determined that the four known tRNAs are the main site of incorporation in vivo, 
while many other RNAs are substrates in vitro.  The azide probes were generated and 
were shown to interact with E. coli TGT, but not as substrates.  In summary, we have 
gained a better understanding of queuine modification of RNAs and have developed 
tools that will aide in future studies. 
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Chapter I 
Queuine 
 
Introduction 
Queuine is one of approximately one hundred modified nucleotides found in 
RNA.1  Since its discovery many details of the modification have been described and its 
potential role examined.  Unlike the majority of modified nucleotides that result from 
modifications of the genetically encoded nucleotides, queuine is incorporated into RNA 
by transglycosylation.2  Eukaryae incorporate queuine obtained through their diet; 
whereas, eubacteria biosynthesize and incorporate the queuine precursor preQ1 before 
completing the modification on the RNA to yield queuine, structure given in Figure 1-1.  
As a result of these differences, the enzyme responsible for the incorporation of the 
modification into RNA, tRNA guanine transglycosylase (TGT), differs between eukaryal 
and eubacterial organisms3.  Recently, the pathway for the synthesis of queuine was 
fully elucidated with all the enzymes involved identified, seen in Figure 1-2.  Presently, 
the queuine modification is known to be present in the wobble position of the 
anticodon loop of tRNATyr, tRNAHis, tRNAAsp, and tRNAAsn .4  Investigations have 
determined that its presence has an effect on codon recognition and has been 
implicated in promoting translational fidelity.         
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Figure 1-1:  Structures of queuine, queuosine, preQ1 and preQ0 
 
Discovery of queuine 
 The discovery of queuine dates to early work performed in the late 1960’s to 
elucidate the sequence and structure of tRNA in various species.  Experiments 
performed to sequence yeast tRNAs5 and E. coli (Phe)6 had demonstrated that Crick’s 
wobble theory7, with the anti-codon recognizing redundant codons (U versus C ending), 
was valid.  The first position of the anticodon, the wobble position, in those tRNAs was 
occupied by either guanosine or 2’-O-methylguanosine.  When similar studies were 
undertaken to determine the sequence of E. coli tRNAtyr, it was discovered that the first 
position of the anticodon was occupied by a different modified guanosine not previously 
observed8.  The new base of unknown structure was denoted as G* by Goodman8b, c, R 
by Doctor8a, and Q by RajBhandary8d. 
 The studies all employed a standard methodology to examine the sequence of 
tRNA.  The desired tRNA was purified from other RNAs by combinations of column 
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chromatography procedures using DEAE-cellulose and DEAE-Sephadex.  The tRNA was 
then digested with bovine pancreatic ribonuclease and ribonuclease T1.  Subsequent 
purification of the fragments allowed for their identification and when compared to 
products from limited hydrolysis with RNase T1, resulting overlapping fragments 
provided a means to determine the overall sequence.  Two dimensional 
electrophorectic separations of the digested nucleotides allowed for their determination 
and the identification of the previously unknown bases.  The investigators postulated 
that the modification of the wobble position of the anticodon to Q must have a specific 
function in the decoding process4. 
 The discovery of Q, queuine, led Harada and Nishimura to examine all the other 
tRNAs from E. coli for the presence of Q4.   They found that queuine was also present in 
the wobble position of three other E. coli tRNAs:  His, Asn, Asp.  The identity of the base 
as queuine was confirmed through two dimensional chromatography, separation 
retention times with DEAE-Sephadex A-25, and UV absorption spectra.  The four tRNAs 
in which queuine was discovered are all tRNAs with redundant codons whose sole 
variation is that of a U or C in the third position, bases to which the wobble position 
binds.  The authors inferred from this finding that queuine modification played a role in 
codon recognition, and decided to study the stimulation of binding for queuine modified 
[14C] aminoacyl-tRNAs to their codons. 
 The authors studied queuine modified aminoacyl-tRNAs without Q (- Q triplet) 
and with Q (+ Q triplet), including [14C]phenylalanyl-tRNAPhe as a control for their study.  
The results, summarized in Table 1-1, demonstrate that when G is present there is no 
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codon preference; however, when Q is present in the wobble position U ending codons 
bind with a greater affinity.  The results also indicate a general increase in binding when 
queuine is present.  From these findings the investigators reasoned that one role of 
queuine could be to increase efficiency of protein synthesis for genes with certain 
codons and to prevent miscoding, which might occur with G.  This latter conjecture 
stemmed from the authors' previous work where they demonstrated that when 
magnesium ion concentrations were raised in vitro translation errors could occur, 
showing the possible need for greater affinity under certain conditions to ensure proper 
code reading.  This work also showed that all of the substrate tRNAs for the modification 
contained a U-G-U sequence in the anticodon loop, a fact that would later be 
determined to be important for recognition by the enzyme responsible for the 
modification2.   
 Aminoacyl-tRNA Bound to Ribosomes (pmoles) 
Aminoacyl-tRNA Triplet - Q Triplet +Q Triplet 
[14C]Tyrosyl-tRNATyr U-A-U 0.11 0.42 
U-A-C 0.11 0.24 
[14C]Histidyl-tRNAHis C-A-U 0.07 1.22 
C-A-C 0.07 0.78 
[14C]Asparaginyl-tRNAAsn A-A-U 0.08 0.98 
A-A-C 0.08 0.64 
[14C]Aspartyl-tRNAAsp G-A-U 0.06 2.86 
G-A-C 0.06 0.85 
[14C]Phenylalanyl-tRNAPhe U-U-U 0.47 1.61 
U-U-C 0.47 1.99 
Table 1-1:  Stimulation of the binding of [14C]aminoacyl-tRNAs containing Q to 
ribosomes by the corresponding triplets (reproduced from work of Harada and 
Nishimura4).  The reaction was carried out in 0.1 M Tris-HCl (pH 7.5) containing 0.01 M 
magnesium acetate for 8 min at 37 °C.  The amounts of [14C]aminoacyl-tRNA in the 
reaction mixture (0.05 mL) were: tRNATyr 12.5 pmoles, tRNAHis 15.6 pmoles, tRNAAsn 13.3 
pmoles, tRNAAsp 12.2 pmoles, and tRNAPhe 13.7 pmoles. 
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 As an aside, this work into the potential for queuine modification to cause a 
redundant codon bias was partially the basis for a recent project in the Garcia lab.   The 
study examined the expression of green fluorescent protein (GFP) from constructed 
plasmids with varied redundant codons for queuine-tRNA amino acids resulting in 
changes to GFP’s mRNA codon usage9.  One plasmid generated an mRNA with all C 
ending codons and another with all U ending codons for the queuine-tRNA amino acids, 
which were compared to naturally occurring coding for GFP.  The expression of the GFP 
was monitored in normal E. coli K13 (DE3) cells as well as tgt knockout E. coli K12 (DE3) 
cells.  The results indicated that synthesis was increased for U ending codons with 
queuine modification present and seemed to indicate that C ending codons were 
translated more slowly without queuine modification. 
Harada and Nishimura, in their conclusions, expressed the belief that knowing 
the structure of the modified base would help to explain the observed changes in 
affinity.  In 1976 the structure of queuine was reported10.  Modified tRNA from rabbit 
liver was isolated as previously described and rigorously purified by subsequent paper 
chromatography and high pressure liquid chromatography.  The authors were able to 
purify 0.6 mg of queuosine (the ribonucleoside of queuine) from the digested rabbit 
liver tRNA, and two forms were extracted.  One included an alternate sugar instead of 
ribose as the minor constituent of the mixture.  The sample proved sufficient for 
analysis by 252Cf plasma desorption mass spectrometry (PDMS) and 1H NMR, from which 
the structure could be determined.  However, Kasai did not assign the stereochemistry 
of the side chain.  The stereochemistry assignments could not be made until a total 
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synthesis of optically pure queuine was completed by Goto in 197911.  Queuine, seen in 
Figure 1-1, was the first tRNA nucleoside discovered to contain a sugar-like moiety as a 
side chain. 
 In order to determine the distribution of queuine in nature, studies were 
conducted on various plant and animal extracts12.  A study by Katze and coworkers 
demonstrated the presence of queuine in bovine amniotic fluid12a with subsequent work 
establishing queuine incorporation in Drosophila melanogaster12b.  These studies 
verified that queuine was not limited to eubacteria, so Katze, Basile and McCloskey 
conducted a more exhaustive study of eukaryotic species for the occurrence of 
queuine12c.  The results of that study are presented in Table 1-2.  The data was obtained 
from a whole cell assay in a serum free media involving L-M cells and monitoring the 
synthesized tRNA for queuine, while varying potential sources of the nutrients12b, 13.  
Interestingly, the studies with the L-M cells demonstrated that the base of queuine is 
required, queuosine is not active in the assay.  The study also included a gas 
chromatography-mass spectrometry method for verification of assigned structures.  In 
addition to the data presented in the table, the authors found queuine in a limited 
number of samples of human amniotic fluid from normal human pregnancies (16 to 28 
weeks gestation) with levels showing a mean of 29 ng/mL (ranging from 2 to 84 ng/mL). 
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Source Amount 
Bovine amniotic fluid (third trimester) 2300 to 3600 ng/mL 
Drosophila melanogaster (wild type and mutants) 0 to 1100 ng/g 
Coconut Water (ripe) 87 to 530 ng/mL 
Bovine pineal body 300 ng/g 
Wheat germ 190 ng/g 
Bovine seminal vesicle (adult) 110 ng/g 
Bovine testicle (adult) 58 ng/g 
Bovine serum (fetal) 33 to 54 ng/mL 
Tomato (fresh, ripe) 21 ng/g 
Bovine milk (whole and skim) 16 to 17 ng/mL 
Bovine serum (calf) 14 ng/mL 
Bovine milk (evaporated skim, canned 12 ng/mL 
Yogurt (commercial and homemade) 4 to 6 mg/g 
Goat milk (fresh) 3 ng/mL 
Goat milk (evaporated, canned) 1 ng/mL 
Human milk 1 ng/mL 
Table 1-2:  Queuine content from natural products (reproduced from the work of Katze 
and coworkers12c). 
  
 The data showed that queuine is found in eukaryotes in addition to eubacteria.  
Katze and coworkers had also demonstrated that queuine as a base was required for 
incorporation into eukaryotes as opposed to eubacteria that use an alternate base (later 
determined to be preQ1) before subsequent elaboration to queuine
14.  The data also 
demonstrated that queuine was likely a dietary nutrient as it could be used in cell assays 
as such.  A study in germ free mice was conducted to further explore the source of 
queuine that leads to queuosine-containing tRNA15.  When germ free mice were fed a 
chemically defined diet devoid of queuine for one year, the four known modified tRNAs 
in the mice no longer contained queuine.  The authors also determined that queuine 
modification of tRNA could be induced by the injection or feeding of queuine.  It was 
also found that feeding the mice queuine-containing tRNA could restore levels of 
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queuine modified tRNA in the mice, implying a salvage mechanism for queuine.  Katze 
and Gündüz went on to determine that queuine is salvaged from queuosine 5'-
phosphate in eukaryotic cells16. 
From queuine's discovery in the late 1960's to the mouse studies by Katze in the 
early 1980's, much had been learned about the modification.  Its structure, location in 
tRNA, and presence in eubacteria and eukarya, although via different routes of 
modification, had been discovered.  The biosynthetic pathway, however, remained 
unknown as well as the enzymes responsible for its incorporation and salvage.  The 
conducted studies did provide a rationale for undertaking further studies required to 
elucidate these pathways.  The near universal distribution in nature and degree of 
complexity of queuine suggested that it has an important function.  In addition, the fact 
that hypomodification of queuine was seen in several cancer cell lines with tumor 
progression halting upon queuine addition to the tumor cells16-17, and that queuine is 
present in reproductive fluids, implied an importance in cell development and 
regulation12c.  
 
Biosynthesis of queuine and incorporation 
 Although queuine and some of its precursors have been known for over 40 
years, its biosynthesis was not fully elucidated until recently18.  In fact until 2004 only 
two of the enzymes involved had been discovered and characterized, namely TGT and 
QueA19.  The enzyme responsible for the incorporation of queuine into tRNA, TGT, had 
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been extensively studied and differences between it in different organisms evaluated20.   
The study of those differences had established the substrate in eubacteria and eukaryae 
as being preQ1 and queuine, respectively.  This demonstrated, along with other studies, 
that queuine is a dietary factor in eukaryae but synthesized in eubacteria.  The synthesis 
of queuine early on was believed to start from guanine, which was confirmed to be from 
GTP as determined by a radio-labeling study21. 
 The laboratory of Crécy-Lagard in 2004 identified four additional genes required 
for the biosynthesis of queuine: QueC, QueD, QueE and QueF.  The genes were 
discovered by comparative genomic techniques including phylogenetic distribution of 
tRNA modification genes, clustering of tRNA modification genes and prediction of 
catalytic mechanisms22.  The study was conducted in Acinetobacter calcoaceticus as it is 
naturally competent, and proves a good choice for gene knockout studies as it is 
efficient at homologous recombination.  Their work started with identifying a GTP 
cyclohydrolase capable of starting the reaction sequence and examining genes encoded 
in proximity to these.  This along with the locations of the tgt and queA genes was the 
starting point, to create an occurrence profile.  The phylogenetic study of related 
species with known sequence led them to identify the genes they believed to be 
associated, due to conserved occurrences in their respective operons.  The genes were 
validated as being involved in preQ1 synthesis with knock outs constructed in A. 
calcoaceticus and subsequent monitoring for queuine by HPLC traces of bulk tRNA 
digests from cultures of the knockout strains.  Analyses of the genes by BLAST 
associated QueC as an ATPase, QueD as a 6-pyruvoyltetrahydropterin synthase (PTPS), 
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QueE as a member of a radical SAM protein superfamily and QueF showing homology to 
type I GTP cyclohydrolases.  Studies subsequently determined that QueF, though it 
shares homology to I GTP cyclohydrolases, in fact catalyzes an NADPH-dependent 
reduction of preQ0
23.  Additional work revealed that the cyclohydrolase required to start 
the synthesis from GTP was in fact FolE24.  Therefore, over the past decade the picture 
for the overall synthesis of queuine began to take shape, as outlined in Figure 1-2. 
 
 
Figure 1-2:  Queuine biosynthetic pathways for eubacteria.  G(34) tRNA refers to tRNA 
with guanine in the 34 position, the anticodon wobble base.  Q refers to queuine and oQ 
refers to epoxy-queuine 25. 
 
 The synthesis begins with conversion of GTP to 7,8-dihydroneopterin 
triphosphate by FolE; the same first step in the biosynthesis of folic acid24, 26.  In the 
following step, QueD catalyzes the conversion of the previous intermediate to 6-
carboxy-5,6,7,8-tetrahydropterin27.  The next step in the pathway is catalyzed by QueE.  
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It was confirmed that QueE is an enzyme of the radical SAM protein superfamily 
containing an iron cofactor in a [4Fe-4S] cluster.    The reaction required the addition of 
SAM to proceed in vitro as well as dithionite to produce the required conditions.  This 
reaction removes what had been the 7-position nitrogen in the purine starting base 
through a radical mechanism, producing the carboxylic acid substituted 
pyrrolopyrmidine substituted at the correct position of the pyrrole ring for generating 
preQ0.  The product of the QueE catalyzed reaction is the heterocyclic portion of the 
previously reported nucleoside analogue cadeguomycin, which had been isolated from 
Steptomyces hygroscopicus28.  It has not been confirmed if this pathway is used to 
generate cadeguomycin, though it would appear likely.  The structure of QueC was 
determined by X-ray crystallography29 confirming it was a member of the ATPase family, 
which was also demonstrated by its sequence containing the conserved PPi loop of 
ATPases30.  The reaction catalyzed by QueC is ATP dependent and utilizes ammonia as 
the nitrogen source to generate the cyano functionality of preQ0.  The final reaction in 
the synthesis of preQ1 is catalyzed by QueF.  QueF is an NADPH dependent enzyme, 
which performs a four electron reduction of preQ0 to generate preQ1
31.  At this point in 
the synthesis of queuine, eubacterial TGT incorporates preQ1 into RNA by 
transglycosylation.  The mechanism of tRNA guanine transglycosylase will be discussed 
in more detail in the following section to allow for a comparison to the eukaryal version 
of the enzyme.  The following steps of the synthesis occur with the modified base 
incorporated into the RNA chain. 
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The first step in the synthesis of queuine after transglycosylation of preQ1 is 
catalyzed by QueA.  The enzyme QueA is responsible for adding the queuine side chain, 
but it does so by addition of an epoxycyclopentandiol ring.  The enzyme was discovered 
as it creates a very noticeable difference, preQ1 in place of queuine, when its activity is 
removed32.  Early on methionine was implicated, but later work demonstrated that it 
utilized S-adenosylmethionine as a ribosyl donor instead19.  The final step from the 
cyclopentandiol epoxide derivative has long been known to be B12 dependent, but the 
enzyme responsible had not been identified33.  The enzyme was recently discovered in 
2010 utilizing the Keio collection, which is a E. coli strain where each of the 4,000 non-
essential genes are individually knocked out allowing for identification of the gene 
required for reduction of the cyclopentadiol epoxide25.  Each strain was grown in 
standard media and tRNA was isolated, digested, dephosphorylated, separated by HPLC 
and analyzed by UV and mass spectrometry to identify the cyclopentadiol intermediate 
and queuine.  Two genes when knocked out yielded the cyclopentadiol intermediate 
during analysis:  yjeS, identified as QueG; and tonB, which is known to be a periplasmic 
protein required for iron and cobalamin transport (further demonstrating the need for 
B12 in the reaction catalyzed by QueG).  BLAST analysis shows that QueG is most similar 
in sequence to corrinoid Fe-S containing proteins from anaerobic halorespiring bacteria 
that act as B12 dependent reductive dehalogenases.  The role of B12 and the exact 
mechanism remain unknown, which is the case with many of the enzymes in this 
pathway.  The genes required and their respective classes of protein have been 
identified, but work remains to fully understand the biosynthetic pathway.  The 
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importance of TGT in the pathway, especially given it is the only enzyme of the pathway 
found in eukaryae, merits further review. 
 
tRNA guanine transglycosylase 
 As mentioned earlier, queuine is an intriguing molecule as it is one of the only 
modifications in which a pre-synthesized modified base replaces the encoded base.  In 
all other known cases, modification arises from a reaction with the encoded base.  The 
enzyme tRNA guanine transglycosylase catalyzes the replacement and thus constitutes 
one of the most important aspects in understanding the queuine modification since this 
enzyme’s specificity for RNA dictates what sites are modified.  The transglycoslylation 
activity was first identified in rabbit reticulocytes during the early 1970s by Farkas34.  
The enzyme was later isolated and purified from numerous organisms14, 19, 35.  Once the 
enzyme responsible for the activity was identified, the Garcia group prepared a 
recombinant form of TGT from E. coli36.  Once expressed and characterized, in vitro data 
demonstrated that the enzyme contained a zinc-binding domain that was important for 
structure and played a role in tRNA recognition37.  Further work showed that product 
release was the rate determining step of the reaction mechanism2, 38. 
Studies in other labs demonstrated that the eubacterial form differed from the 
eukaryae version not only in substrate recognition (preQ1 versus queuine), but also in 
quaternary structure39.  The Kelly lab identified that TGT existed as a heterodimer in 
eukaryae and that the function of the other subunit of the dimer, QTRTD1, is yet to be 
fully understood.  Characterization of this heterodimer by the Garcia lab through 
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recombinant expression validated the protein as the partner with TGT in human and 
demonstrated that the additional subunit was required for the enzyme to function40. 
 Experiments to characterize other TGTs had shown that other substrates were 
accepted and incorporated into RNA by bacterial and eukaryal TGTs.  These include 
dihydroqueuine, guanine, 7-deazaguanine41, as well as some synthetically prepared 
analogues of preQ0
42.  Romier et. al. constructed models of the different TGT binding 
pockets in an attempt to understand the substrate specificities20.  The authors used the 
structure of TGT from Z. mobilis to construct a homology model from the sequence for 
C. elegans, allowing a comparison of the binding pockets for TGT from eubacteria (Z. 
mobilis) and eukaryae (C. elegans).  Prior to constructing the model, seen in Figure 1-3, 
the authors noted that the enzymes are nearly identical in length with sequences that 
are 40 % identical, giving them confidence the enzymes would adopt the same fold.  The 
model illustrates that the substitutions of Cys158 for valine and Val233 for glycine enlarge 
the pocket of eukaryal TGT, which allows for the occupancy of larger substrates like 
queuine.  As it appears the pocket is amenable to accepting alternate substrates and has 
even evolved over time to accept queuine instead of the synthetic precursor preQ1
3 , it 
seems likely that synthesized analogues should be amenable to incorporation by TGT as 
well.   
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Figure 1-3:  Structure A from Z. mobilis (eubacterial) used as template to construct B, a 
homology model of TGT from C. elegans (eukaryal).  Reproduced from the work of 
Romier et. al.20, 
 
 Recognition for TGT was first inferred from the four known sites of queuine 
modification in tRNA.  The anticodon sequence for tRNATyr,His,Asp,Asn all contain a GUN 
sequence, which is preceded by a U in all four cases to give a conserved UGUN 
sequence.  Work in the Garcia lab with isolated and prepared tRNATyr demonstrated that 
TGT was sufficient when supplied with substrate to yield the modification43.  They also 
demonstrated that a mini-hairpin of RNA featuring the anticodon stem-loop sequence 
was also a substrate for the modification.  Subsequent work in the Garcia lab 
demonstrated that a UGU sequence in a loop, like that of the anti-codon, is sufficient for 
recognition by TGT44, and further work by Garcia and Hurt45 also demonstrated that the 
VirF mRNA, containing a hairpin sequence with a UGU in the loop, could be modified at 
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that UGU by TGT.  This work implied that modification of RNAs other than the anticodon 
of the four known tRNAs is possible, but the question remains if this occurs in vivo. 
 
Observations 
 Since its discovery many observations have been made concerning queuine.  
Some of the observations pertain to the possible role of the queuine modification and 
others note effects seen when it is not present.  There are reports that queuine 
modification plays a role in avoiding translation errors46 and others that cite its potential 
importance in determining codon usage47.  Associated with these observations are 
reports that looked at the outcomes of queuine modification or hypomodification.  
There have been many reports that associate queuine deficiency with various cancers 
(lung, ovarian, leukemias, lymphomas among others48).  Reports have also 
demonstrated that inhibition of queuine modification can promote carcinogenesis48g.  
Queuine modification has also been demonstrated to be required for the virulence of 
Shigella flexneri49.  These observations are worth noting as they point to a rationale to 
further explore queuine modification and its potential role in cancer and S. flexneri 
infection, and may also help to elucidate what role queuine modification has in the cell. 
 While queuine modification has effects on the cell, it has not been linked to cell 
growth in bacteria as studies with E. coli demonstrated no change in growth, but did 
note a decrease in survival during stationary phase50.  An effect on survival is also 
reported for S. flexneri as queuine-deficient Shigella were less virulent49.  The effect, a 
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50 % reduction in virulence, was correlated with levels of virF protein being reduced by 
50 %.  In these studies no effect on virF mRNA levels were noted linking to effects on 
translation51.  VirF protein is important as it is a transcriptional activator controlling 
expression of proteins important for intracellular spreading of the organism as well as 
for escaping the immune system52.  Interestingly, overexpression of virF mRNA allows 
Shigella to regain hemolytic activity further demonstrating that the loss was due to 
translational efficiency.  Why this effect on translation occurs has been the subject of 
several studies. 
 The work of Nishimura lab, as previously described above4, showed that the four 
tRNAs in which queuine is found all have redundant codons whose sole variation is that 
of a U or C in the third position, the base to which the wobble position binds4.  This led 
the authors to surmise that queuine modification plays a role in codon recognition.  A 
study of queuine modified aminoacyl-tRNA without Q (-Q triplet) and with Q (+Q 
triplet), summarized in Table 1-1, demonstrated that when Q is present in the wobble 
position, U ending codons bind with a greater affinity.  The results also indicate a 
general increase in binding when queuine is present.  From these findings the 
investigators reasoned that one role of queuine could be to increase the efficiency of 
protein synthesis for genes with certain codons and to prevent miscoding, which might 
occur with G thus explaining the effect seen in the Shigella work involving virF 
translation. 
Queuine modification in relation to codon usage was explored in the work of 
Chiari et. al. on the differences of TGT levels in Drosophila species.  They found that 
18 
 
Drosophila willistoni, which is the only species to primarily uses U/T ending codons 
instead of C ending codons, had higher expression levels of TGT implying the importance 
of queuine modification with U ending codon usage53.  The finding of queuine having a 
preference for U ending codons was also reported in the work of Meier et. al. that 
studied the modification in vivo54.  The authors reported a modest preference but point 
out that the four modified tRNAs represent approximately 15 % of codons, which would 
create a cumulative preference for U ending codons that is much more pronounced.  An 
interesting report from other work shows that the lack of queuine modification in 
tobacco mosaic virus increases read through of the UAG stop codon allowing for the 
synthesis of an alternate protein55.  The work of Frey et. al. confirmed these findings 
with a study that looked at U ending or C ending codons through plasmids transformed 
into E. coli containing β-galactosidase56.  Where a stop codon is placed to test if read 
through occurs, as measured by the activity of the resulting enzyme, the authors 
discovered a 2-fold increase in activity and thus an increase in read through with U 
ending codons when queuine was not present.  This was accomplished by knocking out 
TGT, whereas no change was observed for C ending codons.  Experiments have 
consistently demonstrated that queuine, when present in tRNA, effects binding to U 
ending codons. 
 Early in its discovery, queuine was found to be deficient in cancer cell lines.  
Work by Randerath et. al. demonstrated that this was the case for mitochondrial 
tRNAasp from a Morris hepatoma compared to rat liver mitochondria tRNAasp48b.  The 
authors pointed out this could arise for several reasons.  First, it could be the result of a 
19 
 
general queuine deficiency in the tumor cells due to increased transcription and 
turnover of tRNA observed in tumor cells.  Alternatively, the hypomodification of tRNA 
could be the result of loss of function in TGT, a decrease in its expression, or loss of 
transport of TGT to the mitochondria.  A study by Emmerich, et. al. was later conducted 
examining queuine lacking tRNAs in leukemias and lymphomas48e.  The authors found 
that the extent of under modification with queuine correlated with the grade of the 
malignancy or the cellular proliferative capacity.  They also measured available amounts 
of free queuine in the tissue and determined the amount should be sufficient for 
modification, implicating another cause other than lack of queuine supply.  Related 
work by Huang et. al. with lung cancer tissue from 38 surgically removed tumors from 
different patients came to the same conclusions48c.  The authors went so far as to 
suggest that decreased queuine modification may be a general feature of neoplasms 
and be useful for grading malignancy and predicting survival of cancer patients.  The 
finding of queuine hypomodification in cancer cell lines was also reported by 
Baranowski et. al. in ovarian tumors48d.  An explanation for the cause of the deficiency 
has not yet been reported, but related work shows that queuine at a minimum is 
correlated with cancer etiology and its progression, and could prove to play a larger role 
in tumor suppression. 
 In more recent work by Pathak, Jaiswal and Vinayak, queuine modification was 
studied in regards to effects on levels of tyrosine phosphoprotein and Bcl2 levels48a, 48f.  
In both studies lymphoma was induced in mice by serial transplantation of live Dalton’s 
lymphoma ascites cells and queuine was delivered i.p. to examine what effect it has on 
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cancer associated protein levels as well as on the progression of the lymphoma.  An 
increase in life span by several days was observed for higher doses of queuine, 25 µg 
administered daily.  It was also found that Bcl2 levels decreased and queuine appeared 
to induce cell death.  Tyrosine kinase activities were also down regulated by queuine 
administration.  In addition, the administration of queuine has been found to inhibit the 
cell proliferation of Colo-DM320 cells, PC-12 cells, ascites tumor cells, NIH-3T3 cells, U87 
cells, HepG2 cells and EGF supported proliferation of HeLa cells48a, 57.  The group also 
looked at 7-methylguanine to monitor the effects of TGT inhibition.  With co-
administration of 7-methylguanine, inhibitory effects on queuine levels are not seen, 
indicating that TGT-mediated modification of tRNA with queuine was the source of the 
inhibition of cell growth in the cancer cell lines.  This work provided further proof that 
queuine has an important role in cell regulation, yet the exact role is still unknown. 
 
Impetus for dissertation work 
 It is known that the enzyme responsible for the modification in RNA, tRNA 
guanine transglycosylase (TGT), recognizes a UGU sequence in an RNA hairpin loop (e.g., 
transfer RNA anticodon arm) as a site for modification.  Previous work in our laboratory 
has demonstrated that modification of alternate RNA species (i.e. hairpin minihelix44b, 58 
and 800 base mRNA45) with UGU sequences in a loop can occur in vitro.  Whether or not 
the queuine modification is limited to the four instances in transfer RNA in vivo is a 
question that has remained unanswered.  Queuine has been demonstrated to be 
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important for cellular function although its exact role remains unclear.  Determining if 
queuine modification is present in RNAs, other than the known tRNAs, is important in 
understanding the function of queuine modification and its role in the cell. 
 
Previous syntheses of queuine 
Before commencing our studies, a survey of the literature regarding prior 
syntheses of queuine was required as this would provide valuable information on 
strategies to prepare radio-labeled preQ1 and queuine, and other analogues deemed 
critical to our research plan.  There have been three previous syntheses of queuine.  The 
first was completed by Kondo et al.59 The synthetic route, presented in Scheme 1-1, 
builds upon previous work in Goto’s lab to synthesize the side chain of queuine60. Goto’s 
lab undertook this work in order to determine the stereochemistry of the queuine side 
chain, which had not been reported in Kasai’s report on the structure of queuine10.  In 
addition to the synthesis of the side chain, Goto had also previously synthesized 
queuosine to confirm its structure by total synthesis of optically pure synthetic 
queuine11.  As queuine is the substrate for incorporation in eukaryotes its synthesis was 
of greater interest in pursuing biochemical studies.  The route is a convergent synthesis 
that proceeds via a Schiff base between a protected pyrrolopyrimidine aldehyde and 
protected queuine side chain amine, albeit in a lengthy 19 step process.   
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Scheme 1-1:  The synthesis of queuine by Goto: part I, the synthesis of the side chain, 
part II, the synthesis of the aldehyde of the pyrrolo[2,3-d]pyrimidine, and part III, the 
Schiff base reactions and subsequent reduction and deprotection to yield queuine. 
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The synthesis of the side chain was the first portion completed as it was essential 
for the structural determination of queuosine by total synthesis11, 60.  The second part of 
the synthesis, the aldehyde of the pyrrolopyrmidine, was performed as shown in 
Scheme 1-1.  The route suffers from numerous required protection and deprotection 
steps as well as unintentional modifications that later must be compensated for to 
complete the synthesis, the bromination of the pyrrole portion of the ring for example.  
The idea of utilizing a Schiff base formation to give the desired product was a good plan 
but the long route to the aldehyde is problematic from an efficiency and atom economy 
standpoint. 
The second synthesis of queuine performed by Akimoto et al.61 is much shorter 
and proceeds via a Mannich reaction to incorporate a dibenzylamine regioselectively to 
the C-5 position of a pyrrolopyrimidine precursor, as seen Scheme 1-2.  The protected 
side chain of queuine was subsequently added via an amine exchange reaction.  Its main 
drawback is the requirement of several equivalents of the side chain in a key exchange 
reaction.  In this synthesis, Akimoto utilized the queuine side chain that had been 
synthesized as described previously by Goto11.   In this route, 7-deazaguanine is first 
protected with octanoyl chloride, likely in an effort to gain solubility given the general 
insolubility of the starting material.  The addition of the protected pyrrolopyrimidine to 
a formalin solution and dibenzylamine resulted in a Mannich reaction to give the 
dibenzylamine substituted intermediate.  The authors utilized 1H NMR chemical shifts 
and J values to confirm the structure of the product.  In addition, comparison to spectral 
data of isolated natural product ensured that the correct regioisomer had formed. 
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Scheme 1-2:  The synthesis of queuine by Akimoto that utilizes a Mannich reaction to 
incorporate the queuine side chain.  The side chain was prepared by the same method 
used by Goto11. 
 
The most recent synthesis of queuine by Grub et al.62 employs a different 
disconnection of the molecule, proceeding via a key Mitsunobu reaction to introduce 
the cyclopentenylamine side chain and a subsequent cyclocondensation reaction to 
build up the core heterocyclic moiety, seen in Scheme 1-3.  While relatively 
straightforward and efficient, it requires 11 linear steps.  The use of a cyclocondensation 
of a pyrimidine to generate a queuine precursor, preQ0, by Townsend
63 could have 
served as the inspiration for the authors’ route.  The authors had previously synthesized 
a number of pyrrolo[2,3-d]pyrimidines with alternate side chains as part of a drug 
discovery effort at Eli Lilly around an eventual drug with a pyrrolo[2,3-d]pyrimidine core, 
Pemetrexed, seen in Figure 1-4 64.   The diol protected alcohol side chain was 
synthesized by a method developed by Borchardt65.  The linear nature of the route is its 
main drawback.  The bromination step followed by the immediate pyrrolopyrimidine 
annulation is a low yielding two-step process proceeding in only a 45 % yield.  As the 
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bromination is the eighth step of the sequence, the low yield represents a significant 
loss of material and effort. 
 
 
Scheme 1-3:  The synthesis of queuine completed by Barnett and Grubb62.  The side 
chain is synthesized in a procedure developed by Borchardt65.  
 
 
Figure 1-4:  Pemetrexed is a folate antimetabolite manufactured and marketed by Eli 
Lilly under the brand name Alimta® for the treatment of pleural mesothelioma and non-
small cell lung cancer. 
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Syntheses of queuosine 
In addition to the three previous queuine syntheses, several syntheses of 
molecules related to queuine (either the side chain portion of queuine, queuosine, 
precursors like preQ1 and preQ0, or related pyrrolo[2,3-d]pyrimidine structures) have 
been completed.  Two laboratories have synthesized queuosine.  The most recent 
synthesis is that of the Carell lab in 200766 (Scheme 1-4), which also presented a new 
route to the queuine side chain.  The side chain route is similar to that used by Barnett 
and Grubb62, which had been developed by Borchardt65a.  The lab of Goto also 
completed an additional synthesis of queuosine67 in 1986 to improve upon their earlier 
procedure from 197911.  They modified the route as their previous synthesis had 
required a large excess of the queuine side chain which was undesirable and also 
suffered from a subsequent debromination step which proved to be unreproducible.  
Their second synthesis of queuosine is identical to the previously reported synthesis of 
queuine, except instead of utilizing the benzyl protecting for the pyrrole nitrogen a 
ribose is installed with 2, 3-acetonide and acylated 5-hydroxyl moieties protecting the 
ribose.  Following Schiff base formation and reduction to install the desired 
cylopentenylamine side chain, the protecting groups are removed after by treatment 
with 2N HCl. Subsequent neutralization with Amberlite IR-45 provided queuosine.    
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Scheme 1-4:  Queuosine synthesis completed by Carell lab66:  part I, the synthesis of the 
side chain, part II, the synthesis of the aldehyde of the pyrrolo[2,3-d]pyrimidine, and 
part III, the Schiff base reactions and subsequent reduction and deprotection to yield 
queuosine. 
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 The synthesis of queuosine by the Carell lab is presented in Scheme 1-4.  Similar 
to the previous method by Goto’s lab they employed a Schiff Base formation as the key 
reaction in a convergent synthesis.  Their method is shorter and more atom efficient in 
that unnecessary protecting and directing groups are avoided.   The synthesis of the side 
chain borrows from the earlier work of Borchardt65a, which includes acetonide 
protection of D-ribose, PCC oxidation to excise the 5-position methylene of ribose to 
yield a lactone,  and use of an internal Horner-Wadsworth-Emmons reaction to give the 
cyclopentenone.  The cyclopentenone was then subjected to a Luche reduction to 
generate the desired alcohol stereoselectively.  This is the intermediate used previously 
by Barnett and Grubb to generate their cyclocondensation intermediate.  The Carell lab 
though planned on proceeding through a Schiff base intermediate to form queuosine so 
they performed a Mitsunobu reaction to generate an azide intermediate previously 
utilized by Goto.   
Carell et al. made an important discovery during their synthesis that casts some 
doubt on previous syntheses of queuine and queuosine, as they found that the azide 
intermediate of the side chain can undergo a 3,3 sigmatropic shift of the allylic azide to 
give the enantiomer of the side chain.  The same azide intermediate had been used 
previously by Goto and Akimoto.  The Carell lab modified their procedure based on 
previous work of the labs of Spino, Sharpless and Fokin68 and Young69, which had 
studied allylic azide rearrangements and found that cyclic allylic azides require higher 
temperatures to rearrange.  Thus a lower temperature was used to suppress the 
rearrangement in the case of the queuine side chain.  Carell and co-workers also found 
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they could suppress the undesired rearrangement if they performed the Mitsunobu 
reaction and subsequent Staudinger reduction in a single pot at 0 °C. 
  The synthesis of the heterocyclic portion of the molecule, as seen in Scheme 1-4 
part II, began with the formation of the 7-deazaguanine core through a 
cyclocondensation with 2,4-diamino-6-hydroxy-pyrimidine, which was similar to the 
reaction performed by Grubb for his synthesis of queuine.  It provided the same 
intermediate Akimoto had reported on as the starting point for his synthesis of queuine.   
A coupling to D-(-)-ribose occurred under Vorbrüggen conditions after chlorination of 
the lactam, protection of the excocyclic amine and iodination of the 3-position of the 
pyrrolopyrimidine.  Once the chloro group had been hydrolyzed back to the lactam, the 
molecule was subjected to a palladium catalyzed CO insertion reaction to generate the 
required aldehyde.  With the aldehyde and amine side chain in hand the authors formed 
the Schiff base, reduced it to the secondary amine and removed the benzoyl and 
pivaloyl protecting groups to give queuosine. 
 
Alternate syntheses of queuine side chain 
In addition to the synthesis of the side chain performed by the Goto and Carell 
labs, which had been based on earlier work by Grubb and Borchardt, there are four 
alternate syntheses of the queuine side chain.  The other side chain syntheses had been 
performed by Tanaka and Ogasawara in 199670,  Ovaaet. al.  in 199871, Trost and Sorum 
in 200372 as well as Kim and Miller in 200373.  The synthesis of the side chain by Tanaka 
and Ogasawara builds upon their prior work of generating optically pure (-)-3-endo- 
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hydroxydicyclopentadiene by lipase-mediated transesterification74.  The route is lengthy 
and time consuming at 13 steps from the starting cyclopentadiene and proved to be low 
yielding.  While the synthesis is of academic interest, it is not practical.  The other three 
syntheses of the queuine side chain though merit further consideration. 
The synthesis of the queuine side chain performed by Ovaa et. al. is presented in 
Scheme 1-5.  The key features of the route are a Grubb’s ring-closing metathesis to give 
a cyclopentene scaffold and a [3,3] sigmatropic Overman rearrangement.  The protected 
furanose sugar, mannitol, was procured and after selective removal of the 5,6-
isopropylidene to reveal the diol, treatment with triethylorthoformate and acid catalysis 
afforded rearrangement to give the terminal alkene.  Debenzoylation followed by a 
Wittig olefination gave the diene required for ring-closing metathesis by the Grubb 
catalyst.  The imidate from the alcohol substituted cyclopentene was generated by 
treatment with trichloroacetonitrile and DBU.  The Overman rearrangement to give the 
stereochemistry required for the queuine side chain was achieved by heating the 
imidate at reflux for 4 h.  A protected version of the queuine side chain has been formed 
at this point.  The authors, based on previous reports of glycosylated versions of 
queuine (D-mannose and D-galactose) being extracted from rabbit liver10, also wanted 
to generate the side chain required for the synthesis of those molecules.  Glycosylation 
was accomplished by hydrolysis of the isopropylidene protecting group and selective 
silylation the 5-hydroxyl group, followed by glycosylation of the resultant intermediate 
with the assistance of a catalytic amount of trimethylsilyltriflate (TMSOTf).     
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Scheme 1-5:  Queuine side chain synthesis completed by Ovaa, et. al.71  The boxed 
structure is the protected version of the side chain.   The authors went on to synthesize 
the glycosylated form of the queuine side chain that had been isolated from rabbit 
liver10.   
 
 Trost and Sorum presented a synthesis, seen in Scheme 1-6, for the side chain of 
queuine looking to improve upon prior syntheses72.  They started their synthesis with 
the epoxidation of cyclopenadiene followed by direct formation of the acetonide based 
on previous work by Hancock et al.75.  To achieve the desired epoxide opening and 
acetonide formation, multiple acids (Bronsted and Lewis) were tested before BF3 
etherate was identified as the appropriate catalyst for the transformation.  The 
subsequent oxidation with trifluoroperacetic acid, generated from a mixture of urea-
hydrogen peroxide and trifluoroacetic anhydride, and epoxide opening by elimination 
with lithium diethylamine gave a racemic mixture of the alcohol intermediate.  To 
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resolve their racemic mixture the authors first formed methyl carbonate derivatives 
with methyl chloroformate.  They then performed a asymmetric allylic imidation 
catalyzed by (dba)3Pd-CHCl3 with the ligand shown in Scheme 1-6.  To increase the 
solubility of the potassium phthalimide the authors added tetra-n-hexylammonium 
bromide.  A series of solvent and additive conditions were tried until they found that 
one equivalent of the additive, tetra-n-hexylammonium bromide, in DCM run for 12 h 
from a water ice bath to room temperature gave the best yield and ee(%), 62 % and 98 
% ee.  After cleavage of the phthalimide with ethylenediamine the acetonide protected 
version of the queuine side chain was obtained in a 17 % yield from the starting epoxide.  
The main drawback of this method is the need for the palladium catalyzed ligand 
directed asymmetric allylic imidation, which adds extra cost and effort requirements to 
generate the ligand and prepare the substrate for the reaction.   
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Scheme 1-6:  Synthesis of queuine side chain by Trost and Sorum featuring a palladium 
catalyzed deracemization with pthtalimide. 
 
The final synthesis of the queuine side chain to be described here is shown in 
Scheme 1-7 and was completed by Kim and Miller in 200373.  The authors sought to 
develop a stereoselective synthesis of the side chain based on their prior work with 
amino acids as chiral auxiliaries to derive an asymmetric acylnitroso Diels-Alder 
cycloaddition76.  Their synthesis begins with the hydroxamic acid of boc protected L-
alanine.  Oxidation of the hydroxamic acid forms an acylnitroso intermediate, which is 
trapped with cyclopentadiene to generate the Diels-Alder cycloadduct.  Osmium 
tetraoxide provides the cis-hydroxylation of the alkene to give the diol, which was 
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subsequently protected by acetonide formation with 2,2-dimethoxypropane and a 
catalytic amount of para-toluenesulfonic acid.  Reduction with sodium borohydride 
removed the amino acid auxiliary and hydrogenation cleaved the nitrogen oxygen bond.  
All that remained was the conversion of the allylic alcohol to the allylic amine.  This was 
accomplished by Boc protection of the amine, mesylation of the hydroxyl and base 
induced elimination of the mesylate.  Deprotection of the Boc and acetonide was 
accomplished by treatment with 3M HCl to generate the side chain of queuine.  This 
stereoselective method has the advantage of avoiding the need to resolve a racemic 
mixture as in the previous route or the need to suppress a side reaction as in earlier 
routes to the side chain of queuine. 
 
Scheme 1-7:  Synthesis of queuine side chain by Kim and Miller featuring a key amino 
acid derived acylnitroso Diels-Alder cycloaddition. 
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Syntheses of queuine precursors preQ0 and preQ1 
 In the literature there are three reported routes to preQ0-type molecules.  The 
first route published by the Goto laboratory in 198667 was based on their previous 
synthesis of queuine and queuosine.  The authors utilized the aldehyde they had 
generated earlier for the Schiff base formation of queuosine.  The aldehyde was treated 
with hydroxylamine in ethanol to give an oxime product. The authors completed the 
conversion to the nitrile by refluxing the oxime in acetic anhydride, which also acylated 
the free primary alcohol of ribose.  Deprotection with methanol-ammonia and then 
aqueous HCl before neutralization gave preQ0.  This method for generating preQ0 has 
not been used due to the length of the synthesis.  
 The next reported synthesis of preQ0 was reported by the Townsend lab in 
199663.  The synthesis requires only two steps from commercially available starting 
materials and the method has been used by subsequent groups that required a route to 
preQ0
77.  The synthesis starts with a formylation of chloroacetonitrile with methyl 
formate to form chloro(formyl)acetonitrile.  The reagent formed is a substrate for 
cyclocodensation with 2,6-diaminopyrimidin-4-one to yield preQ0.  This short 
straightforward synthesis provides a quick means to generate preQ0. 
 One other method to generate preQ0 has been published by the Carell lab
78.  The 
synthesis builds on their previous synthesis of queuosine and starts from their iodo 
intermediate.  From this intermediate the authors perform an iodine/magnesium 
exchange reaction with iPrMgCl-LiCl (Turbo-Grignard reagent) to form a Grignard 
intermediate of the iodo pyrrolopyrimidine.  The authors then treated the intermediate 
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with tosyl cyanide to generate the nitrile and thus preQ0.  The methods by Carell and 
Goto have the advantage of generating the nucleoside directly.  However, the method 
by Townsend et. al. produces the form needed for most biochemical experiments, and it 
can be further elaborated to the nucleoside by standard methods if so desired.  Their 
method is also amenable to elaboration to generate preQ1 as well as other 
pyrrolopyrimidines such as cadeguomycin, kanagawamycin, archaeosine, and 
echiguanine A or B.  
 The queuine precursor preQ1 has been synthesized by several methods since its 
discovery.  The first synthesis was performed by the Goto lab and is based on their 
synthesis of queuine67, 79.  The authors used their previously described bromination 
reaction of the methyl substituted pyrrolopyrimidine, seen in Scheme 1-1, which was 
subsequently displaced by azide by treatment with sodium azide in DMF.  After 
treatment with ammonia-methanol to remove acetyl protecting groups from the 
exocyclic amine, the authors reduced the azide to the desired amine and removed the 
other bromine with H2 and Pd/C
79.   The authors also published a method to generate 
the ribose substituted nucleoside version of preQ1 that used the same route with the 
ribose in place of the benzyl group on the pyrrolopyrimidine67.  Akimoto et al.  also 
described a method to generate preQ1 based on their synthesis of queuine
61, 80.  They 
were making a series of analogues to study the effects of queuine analogues on mouse 
L5178Y cells, a leukemia cancer model.  They generated their common 
dibenzylsubstituted intermediate and treated it with methanol-ammonia to give preQ1.  
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In addition to these routes, other authors who had published syntheses of queuine have 
offered their own routes to preQ1. 
 Grubb and Barnett describe a route to get a protected form of preQ1 based on 
the cyclocondensation method they had developed to generate queuine64.  Their 
strategy for queuine, as described in Scheme 1-3, was altered in that instead of using 
the queuine side chain the authors used phthalimide to substitute the 1,3-propane diol.  
The authors could then oxidize the remaining alcohol to an aldehyde and brominate α to 
it, forming the reagent for the cyclocondensation to give the phthalimide version of 
preQ1.  The authors did not describe the method to give preQ1 from this intermediate, 
but one can envision a cleavage of the phthalimide with hydrazine or ethylenediamine 
similar to the reaction used by Trost in Scheme 1-6.  That method was later reported by 
the Carell lab77b.  In that same publication Carell described a method from preQ0 that 
had been generated by the method first described by the Townsend lab63.  The 
attempted to reduce the nitrile or preQ0 with H2 (50 psi) over Pd/C, but only obtained a 
10 % yield of the product.  In 2010, the Carell lab described a synthesis to the nucleoside 
version of preQ1, which likely could be used to generate the heterocycle as well.  From 
their iodo intermediate, that had been generated first for their synthesis of queuine, the 
authors formylated the ring via a palladium catalyzed CO insertion reaction.  The 
aldehyde was then converted to an oxime by treatment with hydroxylamine.  The 
authors unsuccessfully attempted to convert the oxime to the amine with sodium 
borohydride, but were eventually successful by treating with NiCl2-H2O and sodium 
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borohydride.   Having the amine, the authors deprotected the intermediate with sodium 
hydroxide to give the nucleoside form of preQ1.  
 In addition to synthetic organic chemistry methods to generate preQ1 two 
groups have described enzymatic reactions to generate the product.  Both groups 
describe a nitrile oxidoreductase that reduces preQ0 to the amine of preQ1.  The group 
of Iwata-Reuyl reported the study of the enzyme QueF from Bacillus subtilis that is part 
of the biosynthetic pathway to generate queuine23.  In addition, another group reported 
on the enzyme CinQ from Pseudomonas putida,  its version of QueF81.   Iwata-Reuyl 
reports that QueF is an NADPH dependent enzyme, which performs a four electron 
reduction of preQ0.  The authors propose future studies to test the substrate scope of 
the enzyme pointing to it as a novel reaction type that could prove important as a 
biocatalytic agent.   
 
Design of dissertation research to examine the prevalence of queuine 
 The project was designed with two distinct phases and objectives.  The first 
phase of the project involved synthetic work in the Showalter lab to generate the target 
molecules required for the study.  For this project and to complete ongoing work in the 
Garcia lab studying differences between eubacterial and eukaryal TGT, tritium labeled 
substrates for each target molecule, queuine and preQ1, needed to be synthesized.  
Thus, designing and completing a synthesis of each was the starting point for the first 
objective of the project.  The route to queuine and preQ1 needed to be both efficient 
and allow for facile incorporation of a tritium label.  Having access to tritium-labeled 
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preQ1 would allow me to complete the first objective of the project, namely determine 
the prevalence of queuine in E. coli in a general sense, the degree of queuine 
modification and types of RNA that are substrate for the modification.  
In addition, the first phase of my work in the Showalter lab required the design 
and synthesis of azide analogues of preQ1 to commence the second objective of this 
work, namely further exploring the prevalence of queuine through developing a means 
to identify specific sites of queuine modification.  Azide probes based on the structure of 
preQ1 were designed to be substrates for the TGT.  Incorporation of the azide probes 
would allow for subsequent identification of modified RNAs since the azide would allow 
for subsequent elaboration as a means to isolate the modified RNA.  As each target 
molecule was synthesized, I transitioned my percentage of effort from the Showalter lab 
to the Garcia lab to evaluate each molecule in appropriate biological experiments.  My 
final year was spent solely in the Garcia lab. 
  During the second phase of my graduate career, I worked primarily in the Garcia 
lab.  Initial experiments with the tritium-labeled preQ1 afforded me the opportunity to 
examine the prevalence of queuine modification in E. coli by tracking incorporation of 
the radio-label into RNA.  To complete the first objective, three cell lines were utilized to 
conduct the in vitro and in vivo experiments of this study: a ΔqueC knockout of E. coli 
that is unable to synthesize preQ1 so that tritium labeled compound could be 
incorporated exclusively, a Δtgt knockout strain of E. coli that is unable to incorporate 
preQ1 and a wild-type E. coli strain.  To complete the second objective, developing a 
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means to identify sites of queuine modification with the azide probes, the azide probes 
would be examined. 
 Analyses of the azide probes interactions with tRNA guanine transglycosylase 
were undertaken.  This provided the information required to examine if the azide 
probes are substrates for TGT, which would present an opportunity to discover novel 
sites of queuine incorporation into RNA.  Incorporation of a probe with an azide would 
allow for subsequent Staudinger ligation or click reaction to a tethered biotin.  The 
attached biotin would allow for isolation and concentration by streptavidin affinity 
chromatography.  Experiments to determine conditions for Staudinger ligation and click 
reaction with the synthesized azide congeners of preQ1 thus were also an aspect of the 
second objective.  Evaluating the generated azide probes as a means to identify specific 
sites of queuine would complete the second phase of the project. 
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Chapter II 
Synthesis of Queuine and PreQ1 
 
The first objective of our work was the synthesis of queuine and preQ1 as both 
were required for the desired kinetic analysis and prevalence determinations: preQ1 as 
substrate for bacterial TGT and queuine as substrate for the human version of the 
enzyme.  The overall routes required a design that would provide a straightforward 
means of incorporating tritium into the molecule in the final steps to provide the 
desired radio-labeled substrates.  A survey of the literature, as fully outlined in first 
chapter, shows that there are three previous reports on the synthesis of queuine.  That 
of Kondo et al.59 proceeds via a Schiff base between a protected pyrrolopyrimidine 
aldehyde and protected queuine side chain amine in a total of 19 steps.  The synthesis 
of Akimoto et al.61 is much shorter and proceeds via a Mannich reaction to incorporate 
the protected side chain of queuine regioselectively to the C-5 position of a 
pyrrolopyrimidine precursor.  Its main drawback is the requirement of several 
equivalents of the side chain in a key exchange reaction.  The more recent synthesis of 
Grub et al.62 employs a different disconnection of the molecule, proceeding via a key 
Mitsunobu reaction to introduce the cyclopentenylamine side chain and a subsequent 
cyclocondensation reaction to build up the core heterocyclic moiety.  While relatively 
straightforward and efficient, it requires 11 linear steps.  Our strategy was to 
incorporate the best features of previous syntheses toward developing a convergent 
synthesis in which easily accessed side chain amine and core heterocyclic moieties 
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would be condensed via a reductive amination step.  Use of the queuine side chain in 
the reductive amination would provide queuine; whereas, the use of a protected amine 
as an ammonia surrogate would provide preQ1.  Such a scheme would not only provide 
an efficient route to queuine and preQ1 (and other amine congeners) but allow a simple 
means for incorporation of a tritium radiolabel at the end stage of the synthesis, a 
feature lacking in earlier routes.   
The most direct route to the desired heterocyclic moiety of queuine was 
determined to be via elaboration of readily available preQ0 (3)
63 (Scheme 2-1).  The 
synthesis of preQ0 had been accomplished previously in the Townsend and Gangjee 
Laboratories63, 77c.  The respective procedures differ principally in the method of 
synthesis of chloro(formyl)acetonitrile, 2.  The Gangjee lab utilized toluene as the 
solvent, and isolated chloro(formyl)acetonitrile by extraction before proceeding to the 
subsequent cyclization.  The procedure used by the Townsend lab generated the 
reagent in THF and then proceeded directly without isolation to the cyclization.  Both 
groups reported satisfactory yields, so each procedure was examined to determine 
which would best provide preQ0 for our overall synthesis.  The procedure of the 
Townsend lab proved to be the more reproducible method and therefore was used.  
Thus, in a slight modification of the procedure of Migawa et al.63, condensation 
of in situ-generated chloro(formyl)acetonitrile (2) with 2,4-diamino-6-hydroxypyrimidine 
(1) gave preQ0, which was difficult to enter into further reaction due to its poor organic 
solubility.  We decided to address this by evaluating different methods of silylation.  
Initial attempts with neat hexamethyldisilazane catalyzed by ammonium sulfate were 
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unsuccessful, likely due to limited silylation.  A solution to this was drawn from the 
procedure of Barnett and Kobierski82 to first silylate 3 with excess N,O-
bis(trimethylsilyl)acetamide (BSA) and after removing volatiles in vacuo, treat the 
residual oil with trityl chloride in pyridine to provide tritylated preQ0 (4).  The site of 
tritylation, while not important for subsequent reactions, was determined by 1H NMR to 
be on the N-2 position.  
 Scheme 2-1:  Elaboration of preQ0 to key aldehyde 
 
During procedure optimization for the formation of chloro(formyl)acetonitrile, it 
was discovered that the reagent could be isolated as the stable sodium salt.  Employing 
toluene as opposed to THF afforded the salt as a precipitated product.  The salt remains 
stable for a least a year when stored in a desiccator.  This was confirmed by standard 
analysis and utilizing the reagent in the synthesis of preQ0, which is accomplished in 
good yield (96 %).  Toward assessing general utility, a methodology study with the salt 
of reagent 2 was carried out.  Reactions with 6-aminouracil, cytosine and 6-amino-2-
(methylthio)-4-pyrimidinol were subjected to various conditions evaluated for the 
formation of preQ0.  These included several solvent systems (water, DMF, acetonitrile, 
50% aqueous DMF) as well as variations in monomer equivalents and temperature.  
Reaction with 6-amino-2-(methylthio)-4-pyrimidinol returned starting material; 
whereas,  attempted reactions with cytosine resulted in complex mixtures.  Experiments 
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with 6-aminouracil typically returned starting material but did yield product (19 %) in 
50% aqueous DMF buffered with sodium acetate.  The reaction was not reproducible 
with several runs resulting in recovered starting materials.  A review of the literature 
showed only one example (2,4,6-pyrimidinetriamine6) besides that of pyrimidine 1 (or 
pyrimidine 1 modified with an N-4 alkyl chain) which cyclized in the same manner.  
Hence, the reagent appears to have limited utility in the synthesis of annulated pyrrole 
heterocycles. 
Several trials were attempted to transform nitrile 4 to desired aldehyde 5 with 
DIBAL-H before a reproducible method with an acceptable yield was found.  Our initial 
trials attempted to reproduce the results of Olgen et al.83, but yields were poor and 
quite variable.  Additional conditions such as preforming lithium or sodium salts were 
evaluated, as well as catalytic methods (PtO2, Raney nickel) described earlier
77b.  None 
were satisfactory.  A key breakthrough was to utilize silylation of the heterocycle to 
impart sufficient solubility such that reduction could be conducted at a lower 
temperature.  Hence, protected nitrile 4 was silylated with HMDS in refluxing toluene, 
and upon removal of volatiles the remaining glass-like solid was dissolved in 
dichloromethane and cooled to -78 ºC.  DIBAL-H was then added to complete the 
transformation to 5 after mild acidic workup.  Acid hydrolysis of 5 then provided  highly 
insoluble aldehyde 6.42a  The chemistry shown in Scheme 2-1 completed a three-pot 
sequence in an overall 28 % yield to key heterocyclic aldehyde 5 for subsequent entry 
into a reductive amination reaction. 
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With the aldehyde in hand, our attention focused on synthesizing the amine side 
chain of queuine.  A recent synthesis by Klepper et al.66 was deemed to be the best 
available approach and was utilized in our synthesis with some modifications.  Our 
decision to follow this route was based on its length, overall yield and the fact that it 
avoids a [3.3] sigmatropic rearrangement of an allylic azide intermediate that leads to 
racemization, which occurs in earlier routes employing similar intermediates60.  Klepper 
et al. were able to suppress this by conducting the Mitsunobu reaction and subsequent 
Staudinger reduction in the same pot at a reduced temperature.  
 
Scheme 2-2:  Synthesis of protected queuine side chain 
 
As shown in Scheme 2-2, the synthesis of the cyclopentenylamine side chain 
begins with compound 7, which is readily derived from D-ribose.66  This  contains the 
requisite chirality for the two alcohol functions in queuine.  The reactions from 7 to 
alcohol 10 were conducted similarly as previously described,65a, 84 although minor 
adjustments were made in several steps (see Experimental Procedures).  One key 
modification was in the Horner-Wadsworth reaction (from 8 to 9), which was found to 
be more reproducible when a shorter reaction time was used as demonstrated earlier 
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by Smith et al.84b  For the key final step (10 to 11), we modified the procedure of Klepper 
et al. to avoid the use of the hazardous hydrazoic acid in the Mitsunobu reaction.  
Utilizing diphenylphosphoryl azide (DPPA) instead, 11 was procured in good yield with 
careful control of temperature followed by in situ Staudinger reduction.  The four-pot 
route from 7 to 11 proceeded in 14 % overall yield and was highly reproducible.  
Before completing the synthesis, the chiral purity of the amine needed to be 
verified due to possible racemization of the azide intermediate to 11.  As shown in 
Scheme 2-3, this was accomplished by generating the Mosher amide under standard 
amidation conditions85.  Subsequent 19F NMR demonstrated that only one enantiomer 
was present.  This was confirmed by comparing the spectrum of the Mosher amide of 11 
to that of racemic 11, synthesized via an alternate route that failed to suppress the [3.3] 
sigmatropic rearrangement of the allylic azide (see Spectra Data). 
 
Scheme 2-3:  Synthesis of Mosher amide of protected queuine side chain 
 
With key reaction partners aldehyde 5 and amine 11 in hand, the synthesis of 
queuine was completed.  As shown in Scheme 2-4, this was done under standard 
reductive amination conditions to provide penultimate adduct 14 in near quantitative 
yield.  This was entered directly into a global deprotection with methanolic HCl to 
provide queuine which precipiated out of solution as the monohydrochloride salt in 87% 
yield. 
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Scheme 2-4:  Reductive amination and deprotection to produce queuine 
 
Earlier methods used to generate preQ1 (17) have suffered from poor yields
59, 
77b.  Therefore, in Scheme 2-5 a synthesis building on prior experience with aldehyde 5 
was developed.  The reductive amination of aldehyde 5 with trityl amine was 
determined to be the best way to proceed after considering a variety of ammonia 
surrogates.  Reductive aminations with benzyl amine, 4-methoxybenzylamine (PMB) and 
2,4-dimethoxybenzylamine (DMB) all proved successful but their respective adducts 
were difficult to deprotect.  For these adducts, attempts at acidic deprotection failed as 
only the trityl was removed leaving the other amine still protected with the PMB or 
DMB.  Hydrogenolysis techniques using palladium on carbon appeared successful, but 
the resulting product, preQ1, was difficult to isolate from the reaction mixture due to its 
insolubility.  Given the small scale for the reaction that is requisite for radiolabeling, this 
was not a plausible scenario.  Therefore, trityl amine was employed to accomplish our 
goal, as depicted in Scheme 2-5.  The reductive amination required heating to 70 °C to 
achieve reaction but proceeded well giving a 79 % yield.  Global deprotection was 
possible with methanolic-HCl in high yield (89 %), and afforded a simple isolation of the 
product as the monohydrochloride salt.  
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Scheme 2-5:  Reductive amination and deprotection to produce preQ1 
 
With convergent routes developed for the syntheses of queuine and preQ1 
which  shared aldehyde 5 as a common intermediate, all that remained was to 
synthesize each molecule with a tritide source as opposed to the hydride source used 
previously in the reductive amination step.  Moravek Biochemicals was contracted to 
complete the synthesis of tritium labeled versions of the molecules.  The intermediate 
imines of each were prepared and purified by silica gel flash chromatography.  Moravek 
Biochemicals utilized NaBT4 to complete the reductive aminations, which tritium labeled 
the molecules.  The previously described global deprotection gave the desired products, 
which were verified by NMR and mass spectrometry.    
The generated tritium labeled queuine and preQ1 were utilized in a study to 
determine differences in human and E. coli TGT3.  During that work, investigations of 
each substrate versus wild-type enzyme verified previously reported kinetics and 
therefore validated our syntheses of the substrates, with data presented in Figure 2-1.  
This validation allowed for the subsequent results to be reported with confidence and 
demonstrated the utility of our concise, convergent synthesis of queuine and our short 
synthesis of preQ1. 
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Figure 2:1:  Analysis of radio-labeled substrates, queuine and preQ1, verify they interact 
as previously described in the literature from other experiments.  Figure reproduced 
from work of Chen, et. al.3 
 
 In summary, we developed a short, concise syntheses of queuine and preQ1, 
which we believe addresses limitations of earlier syntheses.  The synthesis of queuine 
proceeds in an overall 24 % yield in a five-pot linear sequence from starting pyrimidine 
1, and the synthesis of preQ1 is completed in an overall 20 % yield.  Our routes 
demonstrate the utility of silylation to facilitate reactions of various pyrrolo[2,3-
d]pyrimidine intermediates, which otherwise would be difficult to conduct reliably.  
Furthermore, our syntheses, especially in the facile generation of aldehyde 5, offers the 
E. coli TGT 
preQ1
Human TGT
Queuine
KM
a
(µM)
kcat
a
(10-3 s-1)
kcat / KM
a, b
(10-3 s-1µM-1)
Human TGT
Queuine
E. coli TGT
preQ1
0.26 ( 0.03)
0.05 ( 0.01)
8.22 ( 0.20)
9.57 ( 0.24)
31.57 ( 2.88)
187.16( 19.07)
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possibility of easily accessing related pyrrolo[2,3-d]pyrimidines as well as making further 
analogues of queuine. 
 
Methods and Materials  
 Glassware was oven-dried before use for reactions run under anhydrous 
conditions.  Melting points were determined in open capillary tubes on a Laboratory 
Devices Mel-Temp apparatus and are uncorrected.  The NMR spectra were recorded on 
a Bruker instrument at 500 MHz for 1H and 125 MHz for 13C spectra.  Chemical shift 
values are recorded in  units (ppm).  Mass spectra were recorded on a Micromass 
TofSpec-2E Matrix-Assisted, Laser-Desorption, Time-of-Flight Mass Spectrometer in 
positive ESI mode unless otherwise noted.  TLC was performed on EM Science aluminum 
baked silica gel (SiO2) plates.  Visualization was performed with 254 nm UV light, 
potassium permanganate stain to identify olefins, and 2,4-dinitrophenylhydrazine (2,4-
DNP) stain to identify aldehydes.  Toluene and pyridine were distilled over CaH2.  All 
other reagents were commercially available and used as received.   
 
Experimental Procedures: 
 
Chloro(formyl)acetonitrile (2).  A dry RB flask with a stir bar and under a blanket of N2 
was charged with a suspension of NaOMe (7.14g, 132 mmol) in THF (90 ml).  The 
suspension was cooled to –5 °C in a water ice-salt bath.  Methyl formate (9.0 mL) was 
51 
 
added in a slowly over about 60-90 sec and the solution temperature was maintained 
for 15-20 min. Chloroacetonitrile (8.33 mL, 132 mmol)) was added drop-wise over ~45 
min from an addition funnel with each droplet resulted in a local discharge of yellow 
color.  The mixture was maintained at –5 °C for 2 h during which a very fine suspension 
developed and the solution color became a pale orange.  The bath was removed and the 
mixture was allowed to come to rt over about a l h period.  TLC (EtOAc) of an aliquot 
quenched with a few drops of concd HCl showed a dominant product spot (Rf  0.45).  
The mixture was ice-cooled and treated drop-wise with concd HCl (12 mL) during which 
the color deepened, eventually becoming cherry red.  The suspension was then filtered 
over a small pad of Celite to collect the NaCl and the pad was washed with EtOAc until 
the wash was nearly colorless.  The collected filtrate was concentrated in vacuo at 40 – 
45 °C until most of the volatiles had been removed.  The solution of 2 was used 
immediately or after being well purged with N2 stored in the freezer for future use.  
 
Chloro(formyl)acetonitrile (Sodium salt of 2).  A dry 250 mL 3-neck RB flask was 
equipped with a mechanical stirrer and an addition funnel.  The flask was charged with a 
suspension of NaOMe (10.8 g, 200 mmol) in toluene (100 mL), which was cooled to –5 
°C in a water ice-salt bath.  Methyl formate (37.0 mL, 600 mmol) was added slowly over 
5 min and the solution temperature was maintained for 15-20 min. Chloroacetonitrile 
(12.66 mL, 200 mmol) was added drop-wise over ~1 h from the addition funnel with 
each droplet resulting in a local discharge of yellow color.  The mixture was kept at –5 °C 
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for 3 h and then allowed to come to room temperature, becoming a thick buttery yellow 
suspension after 16 h.  The suspension was filtered on a glass Buchner fritted funnel and 
the collected white solid was washed with EtOAc and dried under vacuum overnight to 
give 23.2 g (93 %) of product:  1H NMR (DMSO-d6) δ 8.50, 8.16 (result of two possible 
isomers of salt; 7:1 ratio of integrals for peaks 8.16:8.50); 13C NMR (DMSO-d6) δ 168.23, 
126.55, 67.78; The material was stored in a desiccator at room temperature.  The 
material maintained its physical and chemical properties for over a year, giving 
comparable yields in subsequent reactions. 
 
2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (3; PreQ0 from 
Sodium salt of 2).  A RB flask was charged with a stir bar, anhydrous NaOAc (0.065 g, 
0.793 mmol), 2,6-diaminopyrimidin-4-one (0.10 g, 0.793 mmol), the sodium salt of 2 
(0.249 g, 1.982 g), glacial acetic acid (0.124 mL) and distilled water (3.2 mL).  The rapidly 
stirring suspension was warmed to 50 °C for 16 h and then refluxed for 1 h.  The 
resulting suspension was cooled to room temperature and collected on a glass Buchner 
fritted funnel.  The light brown solid was washed with portions of water and then 
acetone.  Vacuum drying provided 0.133 g (96 %) of 3:  mp 360 °C (dec); 1H NMR 
(DMSO-d6) δ 11.98 (br s, 1H) 10.74 (br s, 1H), 7.59 (s, 1H), 6.43 (s, 2H); 
13C NMR (DMSO-
d6) δ 158.0, 154.3, 152.1, 128.2, 116.4, 99.2, 86.0. 
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2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (3; PreQ0 from 
free form of 2). A RB flask was charged with a stir bar, anhyd NaOAc (18.2 g, 222 mmol), 
2,6-diaminopyrimidin-4-one (1; 13.32 g, 105.6 mmol) and distilled H2O (170 mL).  The 
rapidly stirring suspension was warmed to 50 °C, and then treated drop-wise with the 
aqueous solution (~40 mL) of chloro(formyl)acetonitrile 2 (from previous step) over a 
~1.5 h period.  The suspension became viscous and beige in color during the addition.  
Total volume at the end of the addition was 210-220 mL. The mixture was stirred at 50 
°C for ~16 h, brought to reflux over an hour, and then refluxed for 1 h.  During this time, 
the suspension darkened a little and became thinner.  The mixture was cooled to rt and 
the solids were collected onto a Buchner fritted funnel.  The light brown solid was 
washed with portions of H2O (~300 mL) and then acetone (~200 mL). The solids were 
then taken up in 300 mL 20 % aq KOH.  After dissolution (~15 min), the deep brown 
solution was treated with charcoal (Norit 211).  After stirring for 30 min, the mixture 
was filtered over Celite and the pad was washed with H2O.   The filtrate was cooled in an 
ice bath and acidified to pH 2-3 with drop-wise addition of concd HCl.  After stirring for 2 
h, the viscous light beige precipitate was collected on a Buchner funnel and washed well 
with H2O.  Vacuum drying over P2O5 provided 12.62 g (68 %) of 3:  mp 360 °C (dec; lit
63 
>360 C); 1H NMR (DMSO-d6) δ 11.98 (br s, 1H) 10.74 (br s, 1H), 7.59 (s, 1H), 6.43 (s, 2H); 
13C NMR (DMSO-d6) δ 158.0, 154.3, 152.1, 128.2, 116.4, 99.2, 86.0. 
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2-Amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile (3; PreQ0 from 
Sodium salt of 2).  A RB flask was charged with a stir bar, anhyd NaOAc (0.065 g, 0.793 
mmol), 2,6-diaminopyrimidin-4-one (0.10 g, 0.793 mmol), sodium salt of 
chloro(formyl)acetonitrile (0.249 g, 1.982 g), glacial acetic acid (0.124 mL) and distilled 
H2O (3.2 mL).  The rapidly stirring suspension was warmed to 50 °C for 16 h and then 
refluxed for 1 h.  The resulting suspension was cooled to room temperature and 
collected on a glass Buchner fritted funnel.  The light brown solid was washed with 
portions of H2O and then acetone.  Vacuum drying provided 0.133 g (96 %) of 3. 
 
4,7-Dihydro-4-oxo-2-[(triphenylmethyl)amino]-3H-pyrrolo[2,3-d]pyrimidine-5-
carbonitrile (4).  A suspension of nitrile 3 (2.10 g, 12 mmol) and DMF (24 mL) under 
nitrogen was treated drop-wise with N,O-bis(trimethylsilyl)acetamide (BSA; 8.9 mL, 36 
mmol).  The suspension was stirred until complete solution was attained (1.5 h) and 
then for a further 1.5 h, and concentrated in vacuo overnight to remove DMF and 
volatiles.  The residual oil was diluted with pyridine (24 mL) and the solution was treated 
with trityl chloride (4.01 g, 14.4 mmol).  The mixture was stirred under N2 at 40 °C for 24 
h and then poured into 5 % aq NaHCO3 (100 mL).  The precipitated solid was collected, 
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washed with H2O, air dried for 1 h, triturated in CH3CN, and oven dried to leave 3.22 g 
(64 %) of 4: mp 195-197 °C; Rf  0.57 (EtOAc); 
1H NMR (DMSO-d6) δ  11.85 (br s, 1H), 
10.69 (br s, 1H), 7.61 (s, 1H), 7.45– 7.20 (m, 15H), 6.46 (s 1H); 13C NMR (DMSO-d6) δ 
157.5, 151.6, 150.3, 14145.1, 134.3, 129.0, 128.2, 127.1, 116.1, 100.1, 85.9, 70.6; MS 
m/z  418.5 (M+H)+, 440.5 (M+Na)+.    
 
4,7-Dihydro-4-oxo-2-[(triphenylmethyl)amino]-3H-pyrrolo[2,3-d]pyrimidine-5-
carboxaldehyde (5).  A suspension of tritylated nitrile 4 (2 g, 4.8 mmol), 1,1,1,3,3,3-
hexamethyldisilazane (HMDS, 2 mL), a few mg of (NH4)2SO4, and toluene (4 mL) was 
heated at reflux until solution was achieved and then for 1 h more.  The solvent and 
excess reagent were removed in vacuo and the resulting oil was dissolved in CH2Cl2 (20 
mL).  The mixture was then cooled in a dry ice-acetone bath and DIBAL-H (6.4 mL of a 
1.0 M solution in CH2Cl2) was added drop-wise over ~15 min. A TLC taken after 3 h 
(spraying the plate with 2,4-DNP solution to monitor aldehyde formation)   showed 
about a 75 % conversion to 5 and the initial solution had turned into a light-colored  
suspension.  Another 2.4 mL of DIBAL-H solution was added and stirring was continued 
for an additional 3 h.  The suspension was quenched with 3.5 mL of 9:1 H2O:HOAc and 
the bath was allowed to come to rt.  The suspension was diluted with 60 - 80 mL of 1:1 
EtOAc:H2O and stirred until the solids had broken up and two layers separated on 
standing.  The layers were separated and the aq phase was further extracted with 
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EtOAc.  After washing the combined extracts with brine and drying over MgSO4, the 
EtOAc extract was slowly filtered over a pad of flash SiO2 (on a frit) which was eluted 
with EtOAc until TLC showed the absence of product.  The combined product fractions 
were concentrated to a solid residue that was triturated in minimal hot EtOAc.  After 
cooling, the solids were collected by filtration and dried to leave 987 mg (49%) of 5 as a 
crème-colored solid:  mp 257 °C (dec);  Rf  0.33 (EtOAc); 
1H (DMSO-d6) δ 11.86 (br s, 1H), 
10.66 (br s, 1H), 10.02 (s, 1H), 7.57 (s, 1H), 7.31 (s, 15H), 7.22 (s, 1H); 13C NMR (DMSO-
d6) δ 185.4, 158.5, 151.5, 151.2, 145.2, 129.1, 128.2, 127.1, 124.3, 120.1, 99.3, 70.6; 
MS m/z 421.2 (M+H)+, 443.2 (M+Na)+; HRMS (ESI) m/z 443.1485 [(M+Na)+; calcd for 
C26H20N4NaO2
+: 443.1484]. Processing of the mother liquor by flash SiO2 column 
chromatography, eluting with EtOAc, provided 322 mg (16%) of a second crop of slightly 
less pure 5, which was suitable for use in subsequent reactions.    
 
2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-carbaldehyde (6).  (a)  From 
deprotection of 5:  A suspension of 100 mg of aldehyde 5 and 2 mL of 9:1 HOAc:H2O was 
stirred at rt for 20 h.  The initial orange mixture became a lighter shade of orange as the 
reaction progressed.  The suspension was diluted with ~3 mL H2O and the solids were 
collected, washed well with H2O.  The solids were triturated in MeOH, collected and 
dried to leave 30 mg (71 %) of 6 as a pale orange solid:  mp 280 ºC, dec (lit2 >300 °C, 
dec); Rf 0.3 (20:2:2:1,  EtOAc:EtOH:acetone:H2O); 
1H (DMSO-d6) δ 12.01 (br s, 1H), 10.69 
57 
 
(br s, 1H), 10.06 (s, 1H), 7.52 (s, 1H), 6.35 (br s, 2H); 13C NMR (DMSO-d6) δ 185.5, 159.0, 
153.8, 153.4, 124.5, 120.4, 98.4;  MS (negative mode) m/z  177.0 (M-1)+;  (b) From 
DIBAL-H reduction of 3:  Silylation of nitrile 3 (3.0 g, 17.1 mmol) with (NH4)2SO4 (0.23 g, 
1.7 mmol),  HMDS (25 ml, 120 mmol)  and toluene (50 mL) followed by DIBAL-H (22.3 
mL of CH2Cl2 solution; 22.3 mmol) reduction  in CH2Cl2 (40 mL) was carried out as 
described above for the synthesis of aldehyde 5.  After 2 h TLC was performed to check 
reaction progress. Additional DIBAL-H (22.3 mL, 22.3 mmol) was added after 2 h and the 
reaction was allowed to come to rt overnight.  The reaction was quenched with 9:1 
HOAc:H2O, and the precipitated solids were collected and washed with H2O.  The solids 
were suspended in H2O and treated with 5N aq KOH until solution was achieved.  The 
solution was clarified with charcoal, and then filtered over a pad of Celite.  The filtrate 
was acidified to pH 3 with 6N aq HCl to precipitate solids, which were collected, washed 
with H2O, and dried to leave 1.38 g (45%) of pure 6. 
 
1-Methoxy-2c2-isopropryliden-α/β-D-ribofuranose (6α/6β) (7).  A solution of D-(-)-
ribose (16.3 g; 108 mmol) and 2,2-dimethoxypropane (33 mL; 269 mmol) in acetone 
(150 mL) was cooled in a water ice-salt bath and perchloric acid (aq. 70 %, 46 73 mmol, 
6.5 mL) was added dropwise.  The water ice bath was removed and the solution was 
stirred at room temperature for 2 h.  Methanol (23 mL; 568 mmol) was added and the 
solution was stirred overnight during which it turned orange.  The solution was cooled in 
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an water ice-salt bath and a solution of sodium bicarbonate (12.8 g in 40 mL H2O) was 
added.  The resulting salt was filtered off and the filtrate was evaporated to 
approximately 30 mL and extracted with dichloromethane.  The organic layers were 
combined and washed with brine and dried over MgSO4.  This was then rotary 
evaporated to an oil and vacuum pumped to give the product as a yellow oil, 20.5 g (93 
%).  Rf = 0.65 (pentane: EE, 7:1) NMR data were identical to those previously reported
66. 
 
(1R,5S,8R)-8-Methoxy-3,3-dimethyl-2,4,7-trioxabicyclo(3.3.0)octan-6-one (8).  The 
following is a slight variation of a previously reported procedure66. Benzene (300 mL) 
was added to a 3-neck RB flask equipped with a mechanical stirrer, Dean-Stark tube, and 
a reflux condenser.  Following a 1 h benzene reflux to remove any H2O, 1-methoxy-2,2-
isopropyliden-α/β-D-ribofuranose (6α/6β) (7; 8.0 g, 3.6 mmol) was added to the flask 
followed by pyridinium chlorochromate (PCC; 33.6 g, 156 mmol).  The mixture was 
refluxed for 16 h, cooled and the benzene was decanted off.  The PCC residue was then 
stirred with CH2Cl2 and the mixture was allowed to stand before the CH2Cl2 layer was 
decanted off.  The combined organic phases were concentrated to 50 mL, filtered 
through Celite, and further concentrated to 10 mL. The solution was filtered through a 
SiO2 plug, using 1:1 hexanes:EtOAc as the eluant.  The filtrate was concentrated to an oil 
that was pumped in vacuo until a solid formed.  The solids were crystallized from hot 
59 
 
hexanes to leave 3.21 g (46 %) of 8: mp 82-83 ºC (lit3 75-76 °C); Rf  0.63 (EtOAc); NMR 
data were identical to those previously reported66. 
 
(4R,5S)-4,5-Isopropylidenedioxy-3-cyclopentenone (9).  The following is a slight 
variation of a previously reported procedure66. Dimethyl methylphosphonate (0.66 mL, 
6.17 mmol) was added to a flask containing THF (35 mL).  The flask was cooled to –78 ˚C 
and n-BuLi (3.86 mL; 1.6 M in hexanes) was added drop-wise over 10 min.  After stirring 
for 30 min, compound 8 (1.16 g, 6.17 mmol) was dissolved in THF (5 mL) and added in 
one portion to the reaction solution.  The reaction was stirred at –78 °C for 2.5 h then 
plunged into a water ice bath for 30 min.  The reaction was quenched with the 
successive addition of 10 mL each of EtOAc followed by H2O, and the mixture was 
stirred for 10 min.  The mixture was then diluted with H2O and the aq phase was 
saturated with NaCl and extracted with EtOAc (7x).  The combined extracts were 
washed with brine, dried over Na2SO4, and concentrated to a yellow oil.  The oil was 
filtered through a plug of SiO2, washing with 7:3 hexanes:EtOAc. The eluant was 
concentrated to leave 0.44 g (47 %) of a clear oil that formed white needles of 9 upon 
standing: mp 70 °C (lit3 71 °C; NMR data were identical to those previously reported66. 
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(3R,4R,5S)-3-Hydroxy-4,5-isoproylidenedioxy-cyclopentene (10).  The following is a 
slight variation of a previously reported procedure66. A solution of enone 9 (0.25 g, 1.62 
mmol) and CeCl3·7H2O (0.604 g, 1.62 mmol) in MeOH (6.5 mL) was cooled in a water ice 
bath.  The solution was then treated portion-wise with NaBH4 (0.123 g, 3.24 mmol) and 
the bath was removed.  The suspension was stirred for 1 h, cooled,  and quenched by 
drop-wise addition of 1N aq HCl such that solution was achieved and pH >4 was 
maintained.  The quenched solution was diluted with H2O and extracted with EtOAc 
(7x).  The combined extracts were washed with brine, dried (MgSO4), and concentrated 
in vacuo to leave 0.243 g (96 %) of 10 as a pale yellow oil: NMR data were identical to 
those previously reported66. 
 
(3S,4R,5S)-3-Amino-4,5-isopropylidenedioxy-cyclopentene (11).  Triphenylphosphine 
(0.369 g, 1.41 mmol) in THF (5 mL) was cooled to -20 °C in a dry ice acetonitrile bath.  
Diisopropyl azodicarboxylate (DIAD; 0.277 mL, 1.41 mmol) was added to the reaction 
drop-wise and stirred for 10 min, during which time the reaction became cloudy white.  
A solution of alcohol 10 (0.2 g, 1.28 mmol) in THF (2 mL) was added to the mixture, 
which was then reaction stirred for 30 min.  The mixture was warmed to 0 °C in a water 
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ice-salt bath and diphenylphosphoryl azide (0.331 mL, 1.54 mmol) was added drop-wise.  
The mixture was stirred for 7 h in the water ice-salt bath after which time additional 
triphenylphosphine (0.369 g, 1.41 mmol) was added.  The mixture was stirred for an 
additional 12 h in the water ice-salt bath before being quenched with H2O (0.5 mL) and 
stirring was continued for 8 h.  The mixture was concentrated in vacuo and then taken 
up in hexanes with a minimal amount of CH2Cl2 to precipitate triphenylphosphine oxide 
byproduct, which was removed by filtration.  The filtrate was then purified by two 
successive SiO2 column chromatographies (eluting with CH2Cl2:MeOH, 7:1) to give 0.137 
g (69 %) of 11 as a yellow oil: Rf 0.5 (3:1, CH2Cl2:MeOH; stained by aq KMnO4 solution); 
NMR data were identical to those previously reported66. 
 
5-[[[(3aR,4S,6aS)-3a,6a-Dihydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-
yl]amino]methyl]-2- [(triphenylmethyl)amino]-1,7-dihydro-4H-pyrrolo[2,3-
d]pyrimidin-4-one (14).  Aldehyde 5 (0.030 g, 0.071 mmol), amine 11 (0.017 g, 0.107 
mmol) and Na2SO4 (0.041 g, 0.285 mmol) were suspended in MeOH (0.6 mL) and the 
mixture was stirred at rt for 6 h.  When complete the reaction mixture was filtered and 
concentrated in vacuo to give the imine, which was verified by mass spectrometry.  The 
imine was added to MeOH (0.6 mL) and the suspension was cooled in a water ice-salt 
bath.  NaBH4 (0.0054 g, 0.143 mmol) was added and the bath removed shortly after the 
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addition.  The reaction was stirred for 4 h and then quenched with saturated aq NaHCO3 
(0.6 mL) followed by stirring for 1 h.  The mixture was diluted with H2O and extracted 
with EtOAc (3x). The combined organics were washed with brine, dried (Na2SO4) and 
concentrated in vacuo to leave 0.057 g (99 %) of 14 as beige crystals: mp 175 °C (dec); Rf 
0.15 (9:1, EtOAc:MeOH); 1H NMR (DMSO-d6) δ 10.63 (br s, 1H), 10.34 (br s, 1H), 7.42 (s, 
1H), 7.30 (d, J = 3.0, 12H), 7.21 (d, J = 3.1, 3H), 6.36 (s, 1H), 5.82 (d, J = 4.9, 1H), 5.76 (d, J 
= 5.6, 1H), 5.13 (d, J = 4.7, 1H), 4.35 (d, J = 5.6, 1H), 3.65 (d, J = 13.7, 1H), 3.55 (d, J = 7.7, 
1H), 1.25 (s, 3H), 1.23 (s, 3H); MS m/z 560.2 (M+H)+;  HRMS (ESI) m/z 560.2673 [(M+H)+; 
calcd for C34H34N5O3
+:560.2662]. 
 
2-Amino-5-[[[(1S,4S,5R)-4,5-dihydroxy-2-cyclopenten-1-yl]amino]methyl]-1,7-dihydro-
4H-pyrrolo[2,3-d]pyrimidin-4-one, monohydrochloride (15; Queuine).  Compound 14 
(0.020 g, 0.036 mmol) in an oven dried flask charged with a stir bar was dissolved in 1.25 
M methanolic HCl (0.3 mL).  The solution was stirred at rt for 2.5 h during which a solid 
precipitated out.  The solid was collected, washed with EtOAc, and dried in a vacuum 
oven to give 9.8 mg (87%) of 15 as a monohydrochloride salt: Rf 0.49 (3:1, MeCN:0.2 M 
NH4Cl); mp 210 °C (dec).; 
1H NMR (DMSO-d6) δ 11.38 (br  s, 1H), 11.07 (br s, 1H), 9.46 (d, 
J = 19.3,  2H), 6.88 (s,1H), 6.61 (br s, 2H), 6.15 (d, J = 6.3, 1H), 5.97 (d, J = 6.1, 1H), 4.46 
(d, J = 4.0, 1H), 4.32 (d, J = 14.0, 1H), 4.27 (d, J = 13.9, 1H), 4.13 (t, J = 5.3, 1H), 4.04 (d, J 
= 4.5, 1H); 13C NMR (DMSO-d6) δ 160.5, 153.1, 139.1, 128.8, 118.1, 109.1, 98.8, 74.1, 
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73.1, 66.9, 42.0, 29.4; MS m/z 278.2  (M+H)+, 300.2 (M+Na)+; HRMS (ESI) m/z 278.1254 
[(M+H)+; calcd for C12H16N5O3
+: 278.1253]. 
 
2-(Tritylamino)-5-((tritylamino)methyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (16).  A 
mixture of aldehyde 5 (100 mg, 0.24 mmol), trityl amine (74 mg, 0.29 mmol) and sodium 
sulfate (68 mg, 0.48 mmol) was added to an oven-dried flask charged with a stir bar.  To 
this was added THF (1.2 mL) and the reaction mixture was stirred at reflux for 6 h.  The 
cooled mixture was filtered and concentrated in vacuo to give imine 6.  The imine was 
resuspended in THF (1.2 mL) and cooled to 0 ºC in a water ice bath.  Sodium 
borohydride (18 mg, 0.48 mmol) was added portion-wise and the bath removed shortly 
after the addition.  The mixture was stirred for 3 h, carefully quenched with water (1.2 
mL) and stirred for an additional 1 h.  The quenched reaction mixture was then further 
diluted with water and extracted three times with ethyl acetate (adding a few drops of 
methanol to help resolve the layers).  The combined extracts were washed with brine, 
dried over sodium sulfate and concentrated to a residue that was purified by flash silica 
gel chromatography.  Elution with ethyl acetate (~ 100 mL) followed by concentration in 
vacuo of product fractions left 125 mg (79 %) of 16 as a yellow solid: mp 175 °C (dec); Rf 
= 0.7 (ethyl acetate); 1H NMR (DMSO-d6) δ 10.64 (br s, 1H, exchanges D2O), 10.20 (br s, 
1H, exchanges D2O), 7.31-7.16 (m, 31H), 6.38 (s, 1H), 3.79 (t, J = 8.1, 1H, exchanges D2O) 
2.98 (d, J = 8.0, 2H); 13C NMR (DMSO-d6) δ 159.52, 150.45, 149.93, 146.71, 145.48, 
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129.12, 128.17, 128.10, 127.03, 126.47, 117.84, 99.83, 70.85, 70.48, 65.40, 15.65; MS 
m/z 664.3 (M+H)+, 686.3 (M+Na)+. 
 
2-Amino-5-(aminomethyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one, monohydrochloride 
(17; preQ1).  A suspension of protected preQ1 (7; 25 mg, 0.04 mmol) and methanolic HCl 
(2 mL of 1.25 M solution) was heated at reflux for 2 h.  After reaching initial solution, 
crystalline product precipitated out as the hydrochloride began to form.  The suspension 
was cooled to room temperature and the precipitate was collected onto a frit, washed 
with methanol, and dried to leave 6 mg (74 %) of 1 as a white solid:  mp 225 °C (dec); 1H 
NMR (DMSO-d6) δ 11.29 (br s, 1H, exchanges D2O), 11.06 (br s, 1H, exchanges D2O), 8.26 
(br s, 3H, exchanges D2O), 6.79 (s, 1H), 6.61 (br s, 2H, exchanges D2O), 4.02 (d, J = 5.2, 
2H; s with D2O wash); 
13C NMR (DMSO-d6) δ 160.41, 153.09, 151.55, 116.77, 111.04, 
98.79, 35.81; MS m/z 180.2 (M+H)+, 202.2 (M+Na)+. 
 
2-Amino-5-(aminomethyl-3H)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (17; 3H-labeled 
preQ1).  Reaction of preformed imine 16 was carried out with 
3H-sodium borohydride as 
described above for the synthesis of cold-labeled 16.  The derived 16 was then 
subjected to the same deprotection reaction conditions as described above for the 
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synthesis of 17.  The collected product 17 had a specific activity of 7.0 Ci/mmol.  It 
showed a chemical purity of 99.5 % by HPLC using UV detection at 256nm and a 
radiochemical purity of 96.1 % by HPLC using radiochemical detection. See Appendix for 
further characterization data.  Note: this reaction was carried out for a fee by Moravek 
Biochemicals. 
 
2-Amino-5-[[[(1S,4S,5R)-4,5-dihydroxy-2-cyclopenten-1-yl]amino]methyl-3H]-1,7-
dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, monohydrochloride (15; 3H-labeled 
queuine).  Reaction of preformed imine 14 was carried out with 3H-sodium borohydride 
as previously described for the synthesis of cold-labeled 1486.  The derived 14 was then 
subjected to the same deprotection reaction conditions as previously described for the 
synthesis of 1586.  The collected product had a specific activity of 7.3 Ci/mmol.  It 
showed a chemical purity of 94.1 % by HPLC using UV detection at 259 nm and a 
radiochemical purity of 99.4% by HPLC using radiochemical detection.  See Appendix for 
further characterization data.  Note: this reaction was carried out for a fee by Moravek 
Biochemicals. 
 
 
Chapter III 
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Investigating the Prevalence of Queuine in Escherichia coli RNA via Incorporation of 
the Tritium-labeled Precursor, PreQ1 
 
It is known that the key enzyme responsible for the queuine modification in E. 
coli RNA, tRNA guanine transglycosylase (TGT), recognizes a UGU sequence in an RNA 
hairpin loop (e.g., transfer RNA anticodon arm) as a site for modification.  Previous work 
in our laboratory has demonstrated that modification of alternate RNA species (i.e. 
hairpin minihelix44b, 58 and 800 base mRNA45) with UGU sequences in a loop can occur in 
vitro.  Whether or not the queuine modification is limited to the four instances in 
transfer RNA in vivo is a question that has remained unanswered.  The interest in 
addressing this question has increased given that it is now appreciated that 60-70% of 
the human genome codes for “non-coding RNA”87.  Determining if the queuine 
modification is present in RNA other than the known tRNA, is important in 
understanding the function of the queuine modification and its role in the cell. 
The incorporation of queuine into RNA via transglycosylation provides an 
interesting and unique point of entry to study the prevalence of this base modification 
as it lends itself to the utilization of designed queuine analogues.  Synthetic radio-
labeled versions of the TGT substrate can be utilized to track the incorporation of 
queuine into RNA.  Eukaryae incorporate queuine obtained through their diet; whereas, 
eubacteria biosynthesize and incorporate the queuine precursor preQ1 before 
completing the modification on the RNA to yield queuine (Figure 3-1).  As a result of 
these differences, the enzyme (TGT) responsible for the incorporation of the 
modification into RNA differs between eukaryal and eubacterial organisms13.3  Tritium-
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labeled preQ1 ([
3H] preQ1) was synthesized along with tritium-labeled queuine 
(described in Chapter II) and both were used in a study that explored differences 
between human and E. coli TGTs, which concluded that divergent evolution from a 
common progenitor led to the eubacterial and eukaryal enzymes3, 86. 
 
 
Figure 3-1:  Queuine biosynthetic pathways for eubacteria and eukarya.  Note the key 
role of TGT and the heterocyclic substrate difference between eubacterial and eukaryal 
TGTs.  G(34) tRNA refers to tRNA with guanine in the 34 position, the anticodon wobble 
base.  Q refers to queuine and oQ refers to epoxy-queuine25. 
 
A number of in vitro and in vivo experiments were conducted utilizing three E. 
coli strains: a ΔqueC knockout (see Figure 3-1) that is unable to synthesize preQ1 
allowing tritium-labeled compound to be incorporated exclusively, a Δtgt knockout that 
is unable to incorporate preQ1 and a wild-type E. coli strain.  The queC gene knockout 
strain was chosen as queC is the first committed step in the queuine biosynthesis 
pathway.  Deletion of queC prevents the biosynthesis of any potential TGT-substrate 
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intermediates, thereby eliminating any competition for incorporation of our labeled 
compound by endogenous unlabeled preQ1 or other intermediates.  The Δtgt strain 
served as an excellent negative control to ensure that the incorporation observed was 
TGT-dependent.  Our studies clearly demonstrate TGT-dependent incorporation of 
radiolabel into ribosomal RNA and non-ribosomal/non-transfer RNA species. 
 
Results 
Total RNA was prepared from E. coli cultures utilizing Epicentre Biotechnologies, 
MasterPure™ RNA preparation kit.  Development of a method to separate the RNA and 
detect sites of incorporation of radio-labeled preQ1 was then undertaken.  We 
separated the RNA species on a polyacrylamide gel and attempted to quantitate 
incorporated radioactivity via phosphorimaging of the dried gel; however, this method 
was not successful in our hands (data not shown), as we were unable to detect any 
bands.  Given the fact that digestion of agarose polysaccharide chains by the enzyme 
Gelase allows for isolation of gel-separated oligonucleotides (via cutting gel bands, 
Gelase digestion and precipitative recovery of the RNA), our focus shifted to utilizing 
agarose gels.  Total RNA was successfully fractionated via excising bands from a low-
melting agarose gel after separation by electrophoresis.  After Gelase digestion of the 
agarose, the RNA would be ethanol precipitated and collected by filtration.  The 
collected RNA could then be subjected to liquid scintillation counting for radioactivity 
quantitation.  Several standards were used as rough size markers for band excision, 
most significant of which is tyrosine transfer RNA that had been prepared in vitro43.  
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Gels were visualized before cutting by UV shadow onto a silica TLC plate containing a 
fluorescent dye; this method was utilized to avoid potential interference of liquid 
scintillation counting by RNA stains (e.g., ethidium bromide).  Figure 3-2 shows an 
example of a gel (stained with ethidium bromide for illustrative purposes) with the 
excision grid depicted. 
 
Figure 3-2:  Example agarose gel of total RNA preparation.  Lane A: 1 kb ladder, B: virF 
mRNA, C: minihelix/hairpin RNA, D: tyrosine tRNA, E: total RNA, and F: total RNA with 
grid showing gel bands for radioactivity determinations. 
 
Total RNA isolated from E. coli ∆tgt and E. coli ∆queC was used for in vitro 
studies.  The RNA from E. coli ∆tgt cannot contain queuine, preQ1 or any intermediate 
incorporated due to the lack of TGT.  The RNA from E. coli ∆queC should not contain 
queuine, preQ1 or any intermediate incorporated as the biosynthesis of preQ1 has been 
interrupted at the first committed step (Figure 3-1).  To ensure that preQ1 and other 
intermediates were not provided to the ∆queC cultures as a nutrient, the culture media, 
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2xTY, consisted of a yeast extract and trypsin hydrosylate of milk casein.  Neither should 
contain preQ1 or queuine, as yeast does not utilize either and the milk protein casein 
was shown by manufacturer assay to be free of oligonucleotides.  Milk protein, even if 
contaminated with nucleotides, would only contain queuine, which is not a substrate for 
the eubacterial TGT.  These suppositions were borne out as both RNA preparations were 
substrates for pure His-tagged E. coli TGT in vitro as shown in Figure 3-345.  Results are 
presented as a bar graph representing the radioactivity in each excised band.  Band 1 is 
the slowest migrating RNA at the top of the gel, and band 8 is the fastest migrating RNA 
at the bottom of the gel.  Band 7 co-migrates with authentic transfer RNA.  Interestingly, 
radioactivity is incorporated in RNA across all bands with the majority being in bands 
that correlate with higher molecular weight RNAs (Figure 3-3). 
 
Figure 3-3:  Radioactivity in gel bands of total RNA isolated from E. coli TG2 and E. coli 
∆queC incubated in vitro with TGT and [3H] preQ1.  A bar graph of DPM for each band 
excised from enzyme and no enzyme controls (n=2).  E. coli strains ± enzyme as depicted 
in inset. 
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As a control, incubations of total RNA with [3H] preQ1 without TGT were 
conducted and exhibited far lower counts (Figure 3-3), which may be due to a small 
amount of [3H] preQ1 non-covalently associating and co-precipitating with the RNA.  
Control experiments were also performed to ensure labeled tRNA would only be 
detected where seen in visualization.  A sample of tRNATyr prepared in vitro was labeled 
and migrated on an agarose gel.  From the visualization, bands of the sample were 
excised and subjected to Gelase digestion followed by ethanol precipitation and 
scintillation.  As expected the band determined to be tRNA contained counts.  A small 
number of counts above background were observed for the adjoining slices, and all 
other bands gave counts indistinguishable from background.  
In an effort to determine if ribosomal RNA is a substrate for TGT, a method to 
exclusively isolate ribosomal RNA was undertaken with the ΔqueC strain.  The isolation 
was accomplished by pelleting the ribosome via ultracentrifugation.  This RNA was 
similarly incubated in vitro with TGT and [3H] preQ1.  Figure 3-4 shows that ribosomal 
RNAs are also substrates for TGT with low counts in bands 7 & 8.  Treatment of the 
ribosome preparation with proteinase K shifted the counts to lower migrating bands, 4-
6, consistent with dissociation of the 70S ribosome into the constituent RNAs. 
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Figure 3-4: Radioactivity in gel bands of ribosomal RNA fractions isolated from E. coli 
∆queC separated on an agarose gel from an in vitro incubation with TGT and [3H] preQ1 
(n=1). 
 
With data from in vitro experiments indicating that the prevalence of preQ1 and 
thus queuine extended beyond the previously known tRNA to be affected, efforts to 
verify the finding in vivo were carried out.  As a control for the in vivo incubations, we 
used the E. coli Δtgt cell line.  Results of total RNA isolated from in vivo incubations of 
[3H] preQ1 with E. coli Δtgt were similar to standard background counts of 60 to 150 
DPM (Figure 3-5).  Therefore, it is clear that any radioactivity detected above 150 DPM 
results from TGT-catalyzed enzymatic modification of RNA (i.e., “TGT-dependent”).  For 
a reference, counts performed during inspections of a lab are considered clean for 
counts under 150 (counts at those levels are a result of background radiation sources; 
materials in building and cosmic radiation). 
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Figure 3-5:  Radioactivity (DPM) of total RNA fractions separated on an agarose gel from 
an in vivo incubation of E. coli ∆tgt with [3H] preQ1.  This experiment establishes the 
background for the in vivo experiments at less than 150 DPM and that counts in other 
experiments are a result of TGT-dependent incorporation of 3H labeled preQ1. 
 
Studies were then conducted under the same conditions with E. coli ΔqueC and 
TGT2 cell lines.  The results shown in Figure 3-6 reveal that the greatest amount of 
incorporation is detected in the transfer RNA band (band 7).  The experiment 
demonstrated that preQ1 can be scavenged by E. coli and used as a nutrient.  Given that 
the known site of TGT modification is transfer RNA and that transfer RNA is very 
abundant in the cell, it was not surprising to see the majority of the counts in that size 
range.  The fact it is clear that radioactivity was present in the other bands verified the 
in vitro data and indicated that the prevalence was more widespread than previously 
known.  Interestingly, similar results were observed with the TG2 cell line (see 
Discussion). 
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Figure 3-6:  Radioactivity in gel bands of total RNA isolated from E. coli TG2 and E. coli 
∆queC incubated in vivo with [3H] preQ1.  Data presented is the average (n=4) DPM.  
Inset: data from bands 1-5 rescaled. 
 
Ribosomes were then isolated from cultures of E. coli ΔqueC incubated in vivo 
with [3H] preQ1.  Half of the ribosome preparation was treated with proteinase K to 
digest the ribosomal proteins and dissociate the ribosomal RNAs prior to gel 
electrophoresis.  As seen in Figure 3-7, the untreated ribosomes exhibit significant 
radioactivity in all bands with the lowest levels in bands 7 & 8.  As for the in vitro 
experiments, treatment of the in vivo ribosome preparation with proteinase K shifted 
the counts to lower migrating bands, consistent with dissociation of the 70S ribosome 
into the constituent ribosomal RNAs. 
To further probe if RNA species other than ribosomal RNA are modified by TGT, 
total RNA was isolated from an in vivo incubation of E. coli ∆queC with [3H] preQ1 and 
treated with a 5’-phosphate-dependent RNA exonuclease, which degrades ribosomal 
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RNA but not other RNAs.  The results presented in Figure 3-8 compare the exonuclease 
digestion data to total RNA results from ∆queC total RNA collected previously.  The 
detected radioactivity decreases for bands 1-5; however, the counts remain 
substantially above background. 
 
 
Figure 3-7:  Radioactivity in gel bands of ribosomal RNA isolated from E. coli TG2 and E. 
coli ∆queC incubated in vivo with [3H] preQ1.  Data presented is the average (n=4) DPM 
for each gel band for both isolated ribosome as well as proteinase K digest of ribosome. 
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Figure 3-8:  Radioactivity in gel bands of 5´-phosphate-dependent exonuclease treated 
total RNA isolated from E. coli ∆queC incubated in vivo with [3H] preQ1.  Data presented 
is the average (treated: n=2, untreated: n=4 ) DPM for each gel band.  Inset: data from 
bands 1-5 rescaled.  5´-Phosphate-dependent exonuclease selectively digests rRNA. 
 
All studies to this point were conducted using agarose gels to separate RNA 
strands.  A potential problem with this method is that it is not a denaturing system, so 
there is the possibility that modified tRNA could associate with other RNA species and 
give misleading data.  To verify the previous results, the total RNA experiment was 
repeated using denaturing gel conditions.  For separating the RNA, a 6 % polyacrylamide 
gel with 8 M urea was determined to be best.  The total RNA was prepared as before 
and after isolation was diluted to a concentration of 700 ng/µL and loaded onto the gel.  
Visualization consisted of staining the gel with ethidium bromide for UV 
transillumination.  Based on a tRNA standard, bands were excised for extraction of RNA 
and detection.  Extracting the RNA from the urea polyacrylamide gels was accomplished 
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by soaking the bands in a 0.5 M ammonium acetate, 0.1 mM EDTA and 0.1 % SDS buffer 
for 12 hours88.  After extraction the samples were ethanol precipitated and washed with 
70 % ethanol to remove impurities.  The RNA was resuspended and dried onto filters for 
scintillation.  The data in Figure 3-9 casts doubt on the previous results as the counts are 
near background for all but the tRNA band and adjacent bands.  The polyacrylamide gel 
method did not allow for loading as much RNA onto the gel as in the agarose 
experiments.     
  
 
Figure 3-9:  Radioactivity in gel bands of total RNA isolated from E. coli ∆queC incubated 
in vivo with [3H] preQ1.  Data presented is the average (n=2) DPM for each band excised 
(n=2). 
 
 In order to better analyze the PAGE experiments, two additional methods were 
attempted.  Instead of extracting the RNA by soaking in buffer, the polyacrylamide gel 
was blotted onto a Zeta-Probe membrane.  The resulting blot was placed in an exposure 
cassette with a TR phosphor storage screen in an attempt to visualize the radioactivity 
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from the blot.  The visualization of the total RNA blot is seen in Figure 3-10 and rRNA in 
Figure 3-11.  Only one band is visible for the total RNA isolation, and its size indicates 
that it is tRNA.  In the visualization of rRNA two bands are visible near one another.  To 
verify these results, the blotting membrane was cut into bands and scintillated to 
determine where radio-labeled preQ1 was present on the blot.  The results of these 
experiments for total RNA are seen in Figure 3-12 and for rRNA are seen in Figure 3-13.  
The result of the scintillation experiments match what is seen in the visualization.  
 
 
Figure 3-10:  Phosphor storage screen image of total RNA blot with TR screen; visualized 
after screen exposed to blot for 7 days. 
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Figure 3-11:  Phosphor storage screen image of rRNA blot with TR screen; visualized 
after screen exposed to blot for 7 days. 
 
 
 
Figure 3-12:  Radioactivity in bands cut from Zeta-Probe membrane blot of PAGE for 
isolated total RNA; isolated total RNA was analysed at three concentrations named in 
legend, 1300 ng/µL, 650 ng/µL and 350 ng/µL; negative control consisted of blotting 
membrane. 
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Figure 3-13:  Radioactivity in bands cut from Zeta-Probe membrane blot of PAGE for 
isolated rRNA; isolated rRNA was analysed at three concentrations named in legend, 
1000 ng/µL, 550 ng/µL and 275 ng/µL; negative control consisted of blotting membrane. 
 
 
Discussion 
The ability to investigate the prevalence of the queuine modification was made 
possible by having a means to separate and detect RNA modified by TGT with tritium-
labeled preQ1.  The use of low-melting agarose gel electrophoresis provided a 
straightforward means to separate RNA by the extent of migration into the gel 
(correlating with RNA size), allowing us to resolve the known modified transfer RNA 
species from RNAs of other sizes.  The low-melting agarose could then be digested to 
allow for precipitation and isolation of RNA from a particular band excised from the gel.  
As shown in Figure 3-2 by the overlaid grid, all lanes with labeled RNA were divided into 
8 equal bands with band 7 representing transfer RNA as determined by control tRNATyr 
electrophoresed in an adjacent lane.  Once band 7 was identified and excised, others 
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were divided and subjected to digestion, RNA precipitation/collection and detection by 
liquid scintillation counting.  This method was determined to give sufficient resolution 
for our purposes by initial studies with in vitro labeled tRNATyr.  It was demonstrated 
that counts were limited in these control experiments to band 7 with a small portion in 
band 6.  Access to [3H] preQ1 with this separation and detection method made the study 
of queuine prevalence possible. 
Results of initial in vitro studies demonstrate that modification of sites other 
than the known transfer RNA species are indeed possible.  Interestingly, while there are 
a significant number of counts in the transfer RNA band (Figure 3-3, band 7), the 
majority of the radioactivity is found in bands corresponding to RNAs that migrate into 
the gel to a much lower extent than transfer RNAs (e.g., bands 1-5).  The reason for this 
is unclear.  Regarding the possibility that the total RNA preparation may not capture 
transfer RNA efficiently, the results of the in vivo studies discussed below clearly show 
high levels of radioactivity incorporation in the transfer RNA band (e.g., band 7 in Figure 
3-6). 
The results of in vitro incubations of isolated ribosomes from E. coli ΔqueC show 
that the fully formed ribosome is also a substrate for TGT (Figure 3-4).  The low counts in 
lane 7 confirm that the counts detected are not due to transfer RNA that may have co-
purified in the ribosome preparation.  The proteinase K-treated sample exhibited a shift 
in counts from lanes 1 & 2 (likely the intact or partially dissociated 70S particle) mostly 
to lanes 4-6 (likely the dissociated ribosomal RNAs).  Note that the E. coli 5S rRNA is 105 
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bases long, similar in size to transfer RNAs (~75 bases), possibly accounting for the 
counts in lanes 6 & 7 of the proteinase K treated sample. 
The results from the in vivo experiments on total RNA as shown in Figure 3-6 give 
data on one hand more consistent with expectations and yet on the other also 
surprising.  Firstly, they show that preQ1 can be taken up and utilized by E. coli as a 
nutrient from the media.  The results also show that transfer RNA is modified to the 
greatest extent.  This is not surprising as transfer RNAs are the species known to be 
modified and exist in a greater abundance than many other individual RNA species.  The 
surprising finding is that modification occurs in RNAs from essentially all other bands 
(e.g., size ranges) at counts significantly above background.  Background was 
determined with the use of TGT knockout cell line, with the data presented in Figure 3-
5.  The fact the modification appears to be much more widespread than the four known 
transfer RNA species encouraged us to attempt to identify the other types of RNA that 
are targeted for modification, rRNA in particular. 
The isolation of 70S ribosomes followed by their subsequent separation and 
detection (as well as ribosomes treated with proteinase K to free the constituent rRNA) 
indicated that rRNA is indeed a substrate for queuine modification.  The culture volumes 
were increased by necessity so that ribosomes could be isolated; preparations from 
cultures smaller than 100 mL were unsuccessful.  The larger culture size also required a 
lower concentration of the [3H] preQ1 due to the scarcity and cost of the material; 
however, the length of the overnight incubation and the concentration of [3H] preQ1 
slightly above its KM for TGT were evidently sufficient to result in efficient incorporation.  
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The data in Figure 3-7 shows the results of these experiments; additionally, Figure 3-14 
shows ethidium bromide visualization with associated DPM charted.  The total counts 
for the bands are well above background and the distribution helps to understand the 
pattern of results seen in the total RNA experiments.  For total RNA experiments it is 
possible that rRNA species represent the majority of the modification seen in the upper 
bands of the gel, due to the fact that rRNA species are more abundant than other 
species, accounting for 80 % of RNA.  However, this would indicate that only a small 
portion of rRNA is modified as the counts are well below that of tRNA.   
To further verify the rRNA as substrate for queuine modification, the use of a 5’-
phosphate RNA exonuclease that exclusively digests rRNA was employed.  The data 
given in Figure 3-8 compares the results to those of the total RNA experiments for the 
∆queC cell line as total RNA from ∆queC was utilized in these experiments.  It clearly 
shows that the counts in the slower migrating RNA species are reduced, consistent with 
the digestion of the rRNA to smaller fragments that might be included in bands 6-8.  The 
fact that counts remain at slower migrating bands (e.g., 1-4) could indicate that other 
RNA species, such as mRNA, are sites for modification.  It is unclear if there is a large 
number of RNAs of differing sizes that are modified in vivo or if there is a smaller 
number of larger RNAs that are modified in vivo and we are seeing them as well as their 
degradation products throughout bands 1-5.  Further studies to isolate and identify the 
modified RNAs are in process. 
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Figure 3-14:  Example gel and radioactivity of ribosomal RNA (untreated and proteinase 
K treated) fractions separated on an agarose gel from an in vivo incubation of E. coli 
∆queC with [3H] preQ1.  I: 2 % low-melting agarose gel stained with EtBr to visualize 
bands; A: 100 bp ladder, B: 70s ribosome, C: proteinase K digested 70s ribosome, D: 
tyrosine tRNA standard.  Bands were excised based on this visualization as represented 
by the grid on the gel and quantified by liquid scintillation counting.  II: Chart presents 
results in DPM for each band. 
 
However, attempts to confirm these results via denaturing PAGE proved 
problematic.  Denaturing PAGE conditions were not utilized for the entire study as they 
do not allow for loading as much RNA, which reduces the counts seen for each band 
making it more difficult to detect low abundant species that are modified.  The results 
from the agarose experiments could be the result of association of modified tRNA with 
other RNA species such as rRNA, which to some extent might be predicted.  The results 
from PAGE analysis followed by soaking the excised bands to detect the presence of 
radio-label gave counts above background for all the bands but not significantly above 
background except in the case of the tRNA and adjacent bands, as seen in Figure 3-9.  
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Subsequent experiments with PAGE were conducted in an attempt to find a more 
definitive confirmation of the results from the agarose experiments.  The 
polyacrylamide gels were run at three concentrations of isolated RNA (either total or 
rRNA) and were blotted onto a Zeta-Probe membrane.  With the RNA on the surface of 
the blotting membrane, visualization of the radio-labeled RNA was carried out with a TR 
phosphor storage screen.  The total RNA visualization showed one distinct band that is 
tRNA.  The rRNA visualization showed two faint bands.  It is possible that only tRNA is 
modified, as would be indicated by the total RNA visualization, but the presence of two 
spots in rRNA visualization is problematic.  Unless, the 8 M urea denaturing condition 
were not sufficient to disrupt the interaction of rRNA and modified tRNA in this rRNA 
enriched sample.  The blots were subsequently cut into bands, as the agarose gels had 
been excised into bands for scintillation counting.  The scintillation results match those 
of the visualization and do not help resolve the uncertainty.  The counts in these 
experiments, even for the visualized bands, are lower than seen in the agarose 
experiments and might indicate there is just insufficient material loaded with the PAGE 
methods to detect modified low abundancy RNAs. 
An interesting observation from our in vivo work with total RNA, as seen in 
Figure 3-6, is that observed incorporation of radio-labeled preQ1 is nearly identical for 
the TG2 and ΔqueC cell lines.  It is known that queuine biosynthesis is controlled by a 
riboswitch89.  A riboswitch is an RNA element that responds to binding by a small 
molecule by affecting the biosynthetic pathway.  The work of the Breaker lab has 
demonstrated that there are riboswitches that bind preQ1 affecting the biosynthesis of 
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queuine by having regulating among other the following genes:  queD, queE, queC and 
queF89a.  When the riboswitch is bound by its small molecule, preQ1, biosynthesis is 
stopped.  Our in vivo studies with total RNA confirmed those findings, as our 
exogenously provided radio-labeled preQ1 must be halting E. coli’s own synthesis to give 
us the nearly identical counts for the TG2 and ΔqueC cell lines.  In fact, our results show 
that the ΔqueC line was likely not required for this portion of our work based on how 
well our provided preQ1 is incorporated in TG2 cells.  However, it is important that we 
had the knockout cells as the azides we will work with next are unlikely to have the 
same effect on the preQ1 riboswitch. 
This study has led to several interesting observations and defined certain 
questions further that ultimately will require further experimentation.  Our in vitro 
studies with labeled preQ1 confirmed previous reports that TGT can recognize and 
modify RNA other than the four known affected tRNAs.  We also demonstrated that E. 
coli utilizes exogenous preQ1, verifying it can enter the cell.  In addition, it was observed 
that the provided preQ1 binds the preQ1 riboswitch.  We have also demonstrated that 
the four known queuine modified tRNAs utilize the majority of the queuine in the cell.  It 
remains possible that queuine modification occurs at locations other than tRNA, but 
those species are either low in abundance or the instances of modification are regulated 
by some other means, possibly localization of the enzyme39.  As modification with 
queuine is possible in vitro for many species of RNA as demonstrated in our in vitro 
experiments, especially given they were conducted in the presence of tRNA in those 
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experiments, a means of regulating modification other than recognition by TGT must 
occur in the cell.   
 
Materials and methods 
Unless otherwise specified, all reagents were ordered from Sigma-Aldrich.  Yeast 
extract and agar were ordered from Fisher Scientific; tryptone from Acros Organics; 
Seaplaque low-melting agarose was from Lonza.  The MasterPureTM RNA Purification Kit 
and GelaseTM Agarose Gel-Digesting Preparation were procured from Epicentre 
Biotechnologies.  The Biodegradable Liquid Scintillation Counting Cocktail Bio-Safe IITM 
was ordered from Research Products International Corporation.  Fluorescent silica 
chromatography plates were acquired from Analtech.  The [3H] preQ1 was obtained 
from a convergent synthesis with radio-labeling as outlined in Chapter II and isolation of 
final compound was carried out by Moravek Biochemicals 3. 
 
Experimental Procedures: 
Isolating total RNA.  E. coli cell strains TG2 and Δtgt were grown overnight at 37 °C on 
LB plates (5.0g tryptone, 2.4 g yeast extract, 7.5 g agar, 5 mL 1M NaOH) while the ΔqueC 
strain was grown overnight at 37 °C on L-Kan plates (50 μg/mL kanamycin).  Individual 
colonies were then isolated and incubated in 3 mL 2xTY broth (8.0 g tryptone, 5.0 g 
yeast extract, 2.5 NaCl) overnight at 37 °C with shaking.  Subsequently, the total RNA 
was isolated following the vendor’s (Epicentre MasterPureTM RNA Purification Kit) 
protocol. 
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Isolation of Ribosomal RNA.  E. coli ΔqueC was grown overnight at 37 °C on L-Kan plates 
(50 μg/mL kanamycin).  Individual colonies were then isolated and incubated in 3 mL 
2xTY broth overnight at 37 °C with shaking.  One mL of overnight culture was added to 
100 mL 2xTY broth and incubated at 37 °C for 3 h.  The cells were pelleted at 5,000 x g 
for 15 min at 4 °C.  The pellet was resuspened in 4 mL of buffer (50 mM Tris-HCl, 10 mM 
MgCl2, 100 mM NH4Cl, 0.5 mM EDTA).  The cell lysis was achieved by four rounds of a 
freeze thaw cycle with addition of 1 µL of PMSF (100 mM in isopropyl alcohol) and 1 µL 
of lysonase bioprocessing reagent, from Novagen, after the last round and incubation 
for 20 min.  Debris was pelleted via centrifugation at 13,000 rpm in a table-top micro-
centrifuge for 10 min.  The supernatant was transferred to a clean tube, treated with 5 
µL of DNase I (1 unit/μL) and held at room temperature for 10 min.  Debris was pelleted 
via centrifugation at 13,000 rpm for 10 min.  The supernatant was transferred to an 
ultra centrifuge tube and 1 mL of 2 M NH4Cl was added.  The remaining volume of the 
tube was filled with microbiology grade mineral oil.  The ribosome pellet was obtained 
by centrifugation at 40,000 rpm with a Beckmann Ti70 rotor (100,000 x g) for 4 h at 4 °C.  
The supernatant was discarded and the pellet rinsed twice with 0.5 mL of buffer (50 mM 
Tris-HCl, 10 mM MgCl2, 100 mM NH4Cl).  Subsequently, 0.5 mL of the buffer was added 
to the tube and the pelleted ribosomes were resuspended overnight at 4 °C. 
 
Proteinase K Digestion of Ribosomal Proteins.  Ribosomes collected from the above-
described ribosome isolation were treated with 1 µL of proteinase K (50 µg/µL).  The 
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sample was incubated at 65 °C for 15 min in a heating block.  The sample was vortexed 
for 10 sec every 5 min during the incubation.  The protein was precipitated with 175 µL 
MPC protein precipitation solution from Epicentre Biotechnologies.  The debris was 
pelleted via centrifugation at 13,000 rpm for 10 min.  The supernatant was decanted 
and the rRNA precipitated by addition of 500 μL of isopropanol.  The tube was inverted 
30 times and then centrifuged at 13,000 rpm for 10 min to pellet the rRNA.  The rRNA 
pellet was washed with 70 % ethanol twice and then resuspended in 5 µL of water. 
 
5’-Phosphate-Dependent RNA exonuclease treatment of total RNA.  Total RNA was 
isolated as described above.  The total RNA was resuspended in 16.5 µL RNase-free 
water.  The exonuclease digestion was conducted following the vendor’s (Epicentre 
mRNA-ONLY™ Prokaryotic mRNA Isolation Kit) protocol.  To the RNA solution 2 µL of the 
supplied buffer and 0.5 µL of RNase inhibitor (20 units) were added.  The 5’-Phosphate-
Dependent RNA exonuclease (1 µL, 1 unit) was then added, and the reaction was heated 
at 30 °C for 60 min in a water bath.  To terminate the reaction 1 μl of 100 mM EDTA (pH 
8.0) was added.  The RNA was subsequently ethanol precipitated, washed with 70 % 
ethanol and resuspended in 5 µL of water.   The sample was ready for analysis by 
agarose gel separation. 
 
In vitro incubations with TGT and [3H] preQ1.  Total RNA isolated from E. coli ∆tgt and E. 
coli ∆queC and ribosomal RNA prepared from E. coli ΔqueC were incubated in vitro with 
TGT and [3H] preQ1.  The reaction conditions were as follows: 5.65 μL enzyme TGT (5 
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μM), 10 μL total or ribosomal RNA, 20 μL 5X bicine reaction buffer, 14 μL [3H] preQ1 (100 
μM, 1 Ci/mmol) and 50.35 μL deionized water.  A no-enzyme control reaction was also 
conducted where the enzyme was deleted and 56.0 μL deionized water was used.  The 
reactions were incubated for 2 h at 37 °C.  Water was removed from the solutions via 
vacuum centrifugation for 2 h and the resulting pellets were resuspended in 10 μL of 
deionized water and then analyzed via agarose gel separation as described below. 
 
In vivo incubation with [3H] preQ1, total RNA.  E. coli Δtgt, ΔqueC and TG2 cell lines 
were cultured with [3H] preQ1 added to the media.  These incubations were conducted 
under the same conditions as described above for total RNA isolation and detection.  
Three mL cultures in 2xTY with 30 µL of [3H] preQ1 (650.6 µM; 1 Ci/mmol) were 
incubated for 12 h at 37 °C.  Cell pellets from two, 1 mL samples from each 3 mL culture 
were obtained via centrifugation at 13,000 rpm in a table-top centrifuge.  The pellets 
were then subjected to total RNA isolation as described above. 
 
 In vivo incubation with [3H] preQ1, ribosomal RNA.  E. coli ΔqueC was incubated in 3 
mL culture of 2xTY 12 h at 37 °C.  One mL of this overnight culture was used to inoculate 
100 mLs of 2xTY with 30 µL of [3H] preQ1 (650.6 µM; 1 Ci/mmol).  The culture was 
allowed to grow at 37 °C with shaking until an OD600 of 0.6 was achieved, approximately 
3 h.  The cells were pelleted via centrifugation at 5,000 x g for 15 min.  The pellet was 
stored at -20 °C prior to ribosome isolation as described above. 
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Low-melting Agarose Gel Electrophoresis and Excision of Bands.  The reaction samples 
were separated by electrophoresis using 2% SeaPlaque low melting agarose gel at 50 V 
for 120 min.  Three RNA species prepared in vitro were used as controls: tyrosine 
transfer RNA (~80 nt), VirF mRNA (~800 nt), and tyrosine transfer RNA anticodon arm 
minihelix (ECYMH, ~25 nt).  Subsequently, the gel was positioned on a silica gel 
chromatography plate and 250 nm UV light was used to visualize the bands via 
shadowing of the fluorescence of the silica plate.  Sample bands were excised (8 per 
lane) and the agarose was digested with GelaseTM following vendors’ protocol.  The 
radioactivity in the resulting samples was determined by collecting the ethanol 
precipitated RNA on Whatman GF/C filters with subsequent liquid scintillation counting 
in 4 mL of BioSafe II cocktail. 
 
Urea Polyacrylamide Gel Electrophorese and Exicsion of Bands.  The reaction samples 
were separated by electrophoresis using 6% polyacrylamide, 8 M urea gel in TBE at 200 
V for 45 min.  Tyrosine transfer RNA (~80 nt) was used as a control.  The gel was stained 
for 2 h with ethidium bromide diluted into TBE.  The bands were visualized and excised 
by UV transillumination at 254 nm. 
 
Recovery of RNA from Polyacrylamide Gel.  Excised bands were macerated and soaked 
for 12 h in a solution of 0.5 M ammonium acetate, 0.1 mM EDTA, and 0.1 % SDS.  The 
Buffer was decanted from the tube and ethanol precipitated.  The precipitate was 
washed twice with a 70 % ethanol solution.  The RNA samples were resuspended in 
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water and dried onto Whatman GF/C filters with subsequent liquid scintillation counting 
in 4 mL of BioSafe II cocktail. 
 
Blot of Polyacrylamide Gel.  Isolated total RNA or rRNA from previously described 
methods was diluted to approximately 1000 ng/µL.  A serial dilution was performed to 
create two additional samples; one with half the concentration and the final with a 
quarter of the initial concentration.  The samples were then separated as previously 
described by PAGE.  When electrophoresis was complete the gel was transferred to a 
Zeta-Probe membrane by semi-dry transfer at 10 V for 40 min.  The membrane was then 
dried overnight.  Once dry the blot was placed in an exposure cassette with a TR 
phosphor storage screen for seven days to develop.  The image was visualized using a 
Typhoon scanner in phosphor storage mode.       
 
Scintillation of Blotting Membrane.  After visualization, the blot of the PAGE 
experiment was cut into eight equal bands per lane.  The bands were subjected to liquid 
scintillation counting in 4 mL of BioSafe II cocktail. 
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Chapter IV 
Synthesis of Azide Probes and other PreQ1 analogues 
 
With prior work demonstrating that the prevalence of queuine extends beyond 
the previously known four transfer RNAs, our attention turned to finding a means to 
identify the specific RNA species modified.  To that end, azide probes were designed 
(seen in Figure 4-1) based on the heterocyclic core of queuine and preQ1 with the intent 
they would be substrates for tRNA guanine transglycosylase (TGT).  If substrates, the 
azide of the probe would allow for a bio-orthogonal reaction.  A reaction to a biotin 
containing reagent would allow for isolation and concentration by affinity 
chromatography.  In this kind of study there are two main concerns for potential probes.  
First, it must be determined that the probe will be recognized by TGT and incorporated 
into RNA similarly to preQ1 and queuine.  Second, the probe must also be stable to the 
conditions of the incorporation and ligation as well as the method of incorporation by 
TGT (e.g., deprotonation of the pyrrole nitrogen to facilitate its attack on the 1′ carbon 
of the RNA-TGT covalent intermediate).  The heterocyclic portion of queuine and preQ1 
is retained in the probe design as it is important for recognition by TGT2.  The first azide 
probe, 18, with a single methylene between the heterocycle and the azide is the most 
desirable as it is the most analogous to preQ1.  The second probe, 19, features an 
additional methylene spacer and was planned due to stability concerns for, 18, which 
with a single methylene between the azide and the heterocycle may be unstable due to 
the azide being able to act as a leaving group given its benzylic like connection to the 
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heterocycle.  The additional methylene unit insulates the azide from the heterocycle 
thus removing the possible instability issue, while hopefully remaining compact enough 
for the active site of TGT.   
 
 Figure 4-1:  Structure of azide probes for evaluation as TGT substrates 
 
Once the probes are completed it will be determined if they interact with TGT 
through kinetic analysis.  In addition, mass spectrometry will be utilized to verify if the 
probes are in fact substrates38.  If substrates for TGT, they will be introduced to the 
ΔqueC E. coli strain, so that the probe may be taken up without competition from 
endogenous preQ1.  Once the RNA from cells grown with an azide probe as nutrient in 
the media is isolated, the bio-orthogonal nature of the azide functionality will be utilized 
to isolate affected RNA strands from unaffected RNA.  The Staudinger ligation reagent 
described by Bertozzi and other will allow for ligation and subsequent isolation by biotin 
strepavidin affinity90.  Similarly, work by Bertozzi and others has also validated using 
click chemistry, both in a copper catalyzed reaction to a terminal alkyne as well as a 
copper free click reaction to a cyclooctyne, to allow for modification that provides a 
means to isolate and concentrate the modified species.  The purification is accomplished 
utilizing the biotin on the opposite end from the Staudinger ligation part of the reagent.   
Once purified, several methods could be attempted to identify the RNA strands 
modified.  For larger RNA strands DNA microarray chip analysis is possible, the limitation 
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being the gene must be present on the microarray to be identified91.  For smaller non-
coding strands, amplifying amounts and purifying for sequencing is a possible solution.  
This would be accomplished by first adding a poly A tail to the isolated RNA using poly A 
polymerase.  The poly A tail could then be used as a degenerate priming site to amplify 
all the isolated RNA strands by PCR to give the complimentary DNA.  To sequence, the 
resulting DNA would be further isolated so strands could be determined by 
pyrosequencing individually92.  Another possible approach for determining the sequence 
of smaller RNA strands has also been devised.  The azide-linked strands of RNA could be 
exposed to a randomized pool of DNA oligonucleotides that contain restriction sites on 
either end.  The primers that bind to the matching sequence of RNA would be pulled out 
of the mixture by utilizing the biotin of the ligated azide probe.  These then could be 
PCR-amplified and subcloned into a plasmid for sequencing.  The resulting sequence 
would be used to probe genome sequence databases for the gene responsible for the 
RNA.  The proposed method is shown in Figure 4-2.  
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Figure 4-2:  Identification of RNA by Randomized Probe Library; Figure provided by Prof. 
Garcia. 
 
Results and Discussion 
The first two routes explored for the synthesis of probe 18 are shown in Scheme 
4-1.  Aldehyde 5 was the starting point for both pathways.  In the initial attempt alcohol 
20 was generated from aldehyde 5 by sodium borohydride reduction in methanol.  The 
first conditions for azide introduction examined were standard mesylation/azide 
displacement.  However, not surprisingly mesylation failed.  A Lewis acid catalyzed 
method shown was attempted and also failed to yield the desired azide93.  Small 
amounts of the product were generated, but the majority of material decomposed 
under the reaction conditions.  Several other Lewis and mineral acids were evaluated, 
but all fared worse than the original conditions.  It is likely the acidic reaction conditions 
are responsible for the decomposition, resulting in a benzylic-type cation from expulsion 
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of the hydroxyl, which readily leads to polymerization.  This called into question the 
stability of the target compound 18.  Another approach, with precedence based on the 
work of Hoops, et. al.94, was attempted.  This involved starting with previously 
generated aldehyde 5, which was transformed to amine 22 in reasonable yield by 
reductive amination95.  Further functionalization by methylation to form the quaternary 
salt 23 was designed to facilitate the subsequent substitution by azide to give product 
21.  However, the reaction was low yielding and contained a large amount of a 
polymeric side product as in earlier reactions.  In addition, attempts to accomplish this 
synthesis from the unprotected aldehyde, which has been synthesized from preQ0 (3) 
directly, were also unsuccessful. 
 
Scheme 4-1:  Attempted routes to generate preQ1 azide analogue 
 
 
An alternate method for substituting a benzylic-type alcohol with an azide was 
discovered in the literature and served as the basis for another route to 1896.  The 
reaction pathway, as shown in Scheme 4-2, also started with alcohol 20.  The alcohol 
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was treated with diphenylphosphoryl azide (DPPA) and 1,8-diazabicyclo[5.4.0]undec-7-
ene (DBU) to effect the transformation to the azide.  The reaction likely proceeds 
through a diphenylphosphoryl intermediate with the released azide displacing the now 
activated alcohol.  Azide 21 was then converted at low temperature to probe 18 by 
removal of the trityl protecting group with TFA in the presence of triethylsilane, acting 
as a scavenger.  This scheme yielded probe 18 in an overall yield of 18 % from the 
starting pyrimidine 1. 
 Scheme 4-2:  Synthesis of preQ1 azide analogue 
 
The synthesis of the alternate azide probe 19, which features an additional 
methylene spacer between the heterocyclic ring and the azide, was based largely on a 
reported synthesis of the alcohol intermediate 28 by Hammond and coworkers97.  Its 
completion was important due to the concerns about the stability of probe 18 with 
respect to TGT's mechanism of incorporation into RNA.  The synthesis, shown in Scheme 
4-3, begins with 1,4-butanediol (23), which was treated with one equivalent of sodium 
hydride for monoprotection with benzyl chloride.  The remaining alcohol group of 24 
was then oxidized to aldehyde 25 with PCC.  Alternate methods for the oxidation were 
attempted that utilized TEMPO98.  Oxidation with TEMPO and bleach failed to give a 
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good yield of aldehyde 25.  Another set of conditions using TEMPO and 
trichloroisocyanuric acid98b were only successful on a small scale.  As the oxidation to 
the aldehyde with PCC proceeded in good yield and at minimal cost, it was retained in 
the route.  Next, aldehyde 25 was brominated α to the aldehyde with 
bromotrimethylsilane and DMSO.  Bromotrimethylsilane can be difficult to work with as 
it is extremely sensitive to atmospheric moisture.  Another method of bromination with 
5,5-dibromobarbituric acid and acetic acid in dichloromethane99 was evaluated as a 
replacement for the bromotrimethylsilane method.  This method failed to give the 
desired product, so the earlier transformation with bromotrimethylsilane was retained.  
The resulting product, 27, was used without purification in the subsequent cyclization 
step to give the deazaguanine core, compound 28, with the appropriate linker.   
This synthesis differed from the previously published report in several ways.  
First, chromatographic purifications after the benzylation and oxidation steps were 
found to be necessary to provide good yields in subsequent reactions.  In addition, by 
changing the solvent concentration of the cyclization reaction, the product can be 
collected as a precipitate, instead of having to employ difficult extraction and 
chromatography steps.  Another difference in our route from the literature procedure 
was in the removal of the benzyl protecting group.  The authors had utilized boron 
trichloride for the deprotection.  This method was found to be cumbersome due to the 
resulting boronates that made extracting the product difficult.  It was determined that a 
transfer hydrogenation with ammonium formate and palladium on carbon was a 
superior method for removal of the benzyl protecting group. 
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Scheme 4-3:  Synthesis of alternate azide probe based on preQ1 
 
Standard conditions to generate probe 19 from alcohol 28 failed.  Attempts were 
made to mesylate the alcohol for substitution with sodium azide, but mesylation did not 
proceed cleanly to a single product.  Mitsunobu conditions were attempted but also 
failed likely due to competing side reactions with the heteroatoms of the 
pyrrolopyrimidine.  Finally, to generate probe 19 from the alcohol we employed a 
similar method as had been used in installing the azide of 18.  As the alcohol of 19 is a 
primary alcohol of an alkyl nature rather than a benzylic type, modifications to the 
reaction conditions were necessary.  Treatment of 19 with DPPA and DBU gave the 
phosphoryl ester of the alcohol instead of going directly to the azide.  The phosphoryl 
intermediate can be isolated and purified.  It is likely that this intermediate also forms in 
the earlier reaction with 20 to activate the otherwise unreactive alcohol into a suitable 
leaving group.  However, in this example the alkyl alcohol is not as activated to 
spontaneous displacement with azide as the benzylic-like alcohol had been previously.  
To complete this displacement, we utilized a literature method that describes the 
transformation of the 6-position alcohol of a sugar to an azide100.  Hence, after the 
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alcohol of 28 was activated by the formation of the phosphoryl ester, this intermediate 
was treated with sodium azide, 15-crown-5 ether and tertabutylammonium iodide to 
complete the substitution to the desired azide probe 19 in an overall 11 % yield. 
 
Scheme 4-4:  Synthesis of azide probe without methylene spacer 
 
The generation of an additional alternate azide probe was investigated.  A probe 
with the azide connected directly to the heterocycle was envisioned as a way to reduce 
the size of the probe and avoid steric interactions that could encumber its incorporation 
by TGT into RNA.  Two proposed routes to a key halogenoazido acetaldehyde 
intermediate are presented in scheme 4-4.  The first route, substitution of starting 1,4-
dibromo-2-butene with sodium azide followed by ozonolysis as based on a procedure 
from the laboratory of Chi-Huey Wong101, was designed to generate 2-
azidoacetaldehyde.  Unfortunately, we were unable to carry out the synthesis as we did 
not have access to a functioning ozonizer.  An alternate route was attempted built on 
our prior experience with forming reagents for ring closures.  Dichloroacetaldehyde 
diethyl acetal was procured but attempts to mono-substitute one chlorine for an azide 
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failed.  Our attempts to hydrolyze the species to the aldehyde also proved problematic 
and thus the route was abandoned.  An additional option considered was to replace the 
ozonolysis of the first route with an osmium tetroxide oxidation and subsequent sodium 
periodate cleavage to give azidoacetaldehyde.  This was attempted on the dibromo 
starting material, but failed to give desired product.  An additional route contemplated a 
Pinnick oxidation of aldehyde 5 (see Scheme 2-1) to the carboxylic acid followed by a 
Curtius rearrangement with DPPA to generate the amine substituted heterocycle.  A 
Sandmeyer-type reaction would then provide the desired azide.  This latter route was 
not explored due to time and financial constraints. 
In order to use the probes as intended, the Staudinger ligation reagent had to be 
prepared.  The synthesis, seen in Scheme 4-5, was performed as described in the 
literature from commercially available materials102.  With the synthesis of the 
Staudinger ligation reagent, all molecules required for the second phase of the project 
had been made.  Experiments to determine if the azide probes interact with TGT can be 
undertaken, and the Staudinger ligation reaction can be attempted to purify and 
concentrate modified RNA for identification. 
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Scheme 4-5:  Staudinger ligation, synthesis and interaction with azide probes 
 
In addition to the azide probes, the syntheses of several potential inactivators of 
TGT were planned.  An irreversible inhibitor of TGT would be a useful tool in the study of 
queuine prevalence as well as in future work studying the role of queuine.  Routes to 
several possible inactivators were designed, seen in scheme 4-6.  The potential 
inactivators were designed as preQ1 analogues, with leaving groups in place of the 
primary amine of preQ1.  The molecules would benefit from the recognition of the 
pyrrolopyrimidine core for the binding site and have the capability of inactivating TGT 
through a substitution reaction with an amino acid residue in the active site of the 
enzyme.  It would be of interest to know if the cysteine in the active site of the 
eubacterial version of TGT, but not found in eukaryotic version3, would make for 
inactivators that are selective for the eubacteria TGT.  The potential inactivators were 
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based on previous work performed in the Garcia lab in which the fluoro analogue of 
preQ1 was generated and tested
94.  The route described in their paper was low yielding 
and difficult to carry out due to solubility issues, thus we thought that our experience 
with generating preQ1would provide us with a better route. 
 
Scheme 4-6:  Synthetic routes of potential TGT inactivators 
 
The first route attempted was identical to that described in the previous paper94 
with the exception we utilized our trityl protected aldehyde 5 whereas previously the 
unprotected form had been used.  The route started with a reductive amination of 5 to 
the dimethylamine derivative.  Further methylation of the dimethylamine derivative 
formed in situ the quaternary ammonium salt as a leaving group for subsequent 
substitution with fluorine from addition of KF.  The reaction did not yield product, but 
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instead gave a complex mixture.  A modern method of installing fluorine was then 
examined via conversion of a primary alcohol to a fluoride with diethylaminosulfur 
trifluoride (DAST).  This reaction also produced polymeric mixtures without any trace of 
the desired product.  The same transformation was also examined with X-talE, the 
tetrafluoroborate salt of DAST.  This reaction too resulted in multiple products and 
polymer.  Based on these results, the fluorine substituted preQ1 analogue, if formed, 
was deemed too reactive to be useful for subsequent enzymatic reaction and thus was 
abandoned. 
Although the chloro analogue would likely be more reactive than fluoro, the 
previous success we had experienced with DPPA gave us reason to attempt the 
formation of this potential inactivator with diphenylphosphoryl chloride (DPPCl).  The 
reaction conditions appeared to produce a new product, seen by TLC analysis, so NMR 
of the crude mixture was attempted.  The NMR appeared to contain two molecules one 
of which was potentially the desired product.  A silica gel flash column was performed to 
separate the two molecules.  Upon loading the dissolved mixture to the column, it 
turned pink and no material was collected even after extensive flushing with polar 
solvent, indicating the acidity of the silica gel had broken down the product.  It would 
appear that the chloro analogue, if could be generated and isolated, would likely be too 
unstable for biological conditions; therefore, further experiments to generate it were 
not attempted. 
  The deprotected alcohol was generated according to the approach in shown in 
Scheme 4-6.  Aldehyde 5 was first reduced to the alcohol with sodium borohydride, as 
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had been performed in the generation of azide probe 18.  The trityl protecting group 
was removed under the same conditions used to yield azide probe 18.  The product 
precipitated under those condition as had the azide analogue.  Analysis by mass 
spectrometry and 1H NMR indicated the product had formed, but it decomposed in 
solution during further NMR analysis.  The alcohol had been generated to offer alternate 
routes to analogues or to use as an inhibitor as the alcohol is capable of hydrogen 
bonding with heteroatom residues in the active site or potentially be an inactivator 
given the reactive nature of the benzylic like connection.  Biological evaluation was not 
attempted as the molecule was too unstable in solution: DMSO, H2O, or buffered 
aqueous conditions.  The fact the alcohol analogue was too unstable to use ruled out 
any further attempts to make the fluoro, chloro or related analogues. 
 
Methods and Materials  
 Methods and materials used are identical to those of Chapter II. 
 
Experimental Procedures: 
 
5-(Hydroxymethyl)-2-(tritylamino)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (20).  An ice 
cold suspension of 4-oxo-2-(tritylamino)-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidine-5-
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carbaldehyde1 (0.10g; 0.24 mmol)  in methanol (1 mL) was treated with sodium 
borohydride (0.027 g; 0.71 mmol).  The reaction was monitored by TLC, aided by 2,4 
DNP visualizing agent to determine when no aldehyde remained.  After 3 h, the mixture 
was quenched with 3 mL of brine, and extracted with dichloromethane.  The combined 
extracts were dried over magnesium sulfate and concentrated to leave 0.099 g (98.6 %) 
of a white powder as the product.  Rf 0.33 (EtOAc); 
1H NMR (DMSO-d6) δ 10.69 (br s, 
1H), 10.51 (br s, 1H), 7.41 (br s, 1H), 7.31-7.20 (m, 15H), 6.34 (s, 1H), 4.95 (br s, 1H), 4.41 
(d, J = 5.6, 2H); MS m/z 445.1 (M+Na)+.     
 
5-(Azidomethyl)-2-(tritylamino)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (21).  A 
solution of alcohol 20 (0.05 g, 0.12 mmol) in THF (1 mL) was treated with 
diphenylphosphoryl azide (DPPA) (0.031 mL, 0.142 mmol).  The reaction was cooled to 0 
ºC and 1,8-diazabicycloundec-7-ene (DBU) (0.021 mL, 0.142 mmol) was added drop-
wise.  The reaction was stirred for 4 h and an additional equivalent of DPPA and DBU 
each was added after 4 h.  After 18 h total reaction time, the reaction was quenched 
with a 1:1 mixture of diethyl ether and water (5 mL).  Additional ether and water were 
added and the organic layer was extracted and washed with water (2x) and brine.  The 
organic layer was dried over sodium sulfate and concentrated to give a yellow powder, 
which was purified by SiO2 chromatography (gradient from 8:2, hexanes:ethyl acetate, 
to 1:1, hexanes:ethyl acetate).  Product fractions were concentrated in vacuo to leave 
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0.050 g (94 %) of the product as a white powder.  Rf 0.52 (1:1, hexanes:ethyl acetate); 
1H 
NMR (DMSO-d6) δ 10.94 (br s, 1H), 10.36 (br s, 1H), 7.42 (br s, 1H), 7.31-7.20 (m, 15H), 
6.58 (s, 1H), 4.31 (br s, 2H); MS m/z 459.1 (M+Na)+, 895.3 (2M+H)+. 
 
2-Amino-5-(azidomethyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (18).  Starting azide 
(0.10 g, 0.022 mmol) and triethylsilane (3.57 µL, 0.022 mmol) were dissolved in 
dichloromethane (0.5 mL) and stirred until solution was achieved.  The mixture was 
cooled to -78 ºC, and treated with trifluoroacetic acid (3.32 µL, 0.045 mmol).  The 
reaction mixture was stirred at -78 ºC for 3 h, and then allowed to warm to room 
temperature.  A formed precipitate was collected and dried to leave the product (0.039 
g, 85 %). as an off white powder. 1H NMR (DMSO-d6) δ 11.11 (br s, 1H), 10.44 (br s, 1H), 
6.76 (s, 1H), 6.20 (br s, 2H), 4.38 (s, 2H); 13C NMR (DMSO-d6) δ 158.69, 157.95, 152.39, 
116.95, 111.07, 98.32, 45.65; MS m/z 228.0 (M+Na)+, 433.1 (2M+Na)+; HRMS (ESI) m/z 
228.0611 [(M+Na)+; calcd for C7H9N5ONa
+:  228.0610 ].   
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4-Benyloxybutan-1-ol (24).  The product was prepared as previously described97.  The 
product was purified by SiO2 chromatography (gradient, hexanes to ethyl acetate) to 
afford 8.4 g (71 %) of product as an oil.  Rf 0.26 (8:2, hexanes:ethyl acetate).  The 
1H 
NMR was the same as previously described97.   
 
4-benzyloxybutanal (25).  The product was prepared as previously described97.  The 
reaction solution was separated from the insoluble PCC by celite filtration. The solution 
was distributed between ether and water.  The combined organic layers were filtered 
through a plug of SiO2 to give a clear yellow oil.  The product was purified by SiO2 
chromatography (gradient, hexanes to ethyl acetate) to afford 2.75 g (69 %) of product.  
Rf 0.67 (3:2, hexanes:ethyl acetate).  The 
1H NMR was the same as previously 
described97.   
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2-Amino-5-(2-(benzyloxy)ethyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (27).  Aldehyde 
25 (0.9 g, 5.05 mmol) was dissolved in acetonitrile (10 mL) and cooled to 0 °C.  
Bromotrimethylsilane (0.784 mL, 6.06 mmol) and DMSO (0.430 mL, 6.06 mmol) were 
added drop-wise.  The reaction mixture was stirred at room temperature for 4 h.  A 
suspension of 2,6-diaminopyrimidin-4-one (0.701 g, 5.55 mmol) in water (12 mL) was 
added as a single charge.  The mixture was stirred for 18 h, during which a white 
precipitate formed.  The precipitate was collected by vacuum filtration on a glass 
Buchner fritted funnel and triturated in acetonitrile to obtain 0.75 g (52 %) of product as 
a cream colored powder.  Rf 0.44 (4:1, ethyl acetate: methanol).  The 
1H NMR was the 
same as previously described97.   
 
2-amino-5-(2-hydroxyethyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (28).  A mixture of 
benzyl protected alcohol 27 (0.5 g, 1.76 mmol) and ammonium formate (1.109 g, 17.6 
mmol) was dissolved in methanol (7 mL).  Upon heating to reflux, 10 % Pd/C (0.187 g, 
0.176 mmol) was added to the mixture.  After 8 h the reaction mixture was filtered 
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through a pad of celite and concentrated in vacuo to a grey solid.  The solid was 
triturated in hot ethyl acetate to give 0.2 g (59 %) of the product as a white powder.  Rf 
0.40 (4:1, ethyl acetate: methanol).  The 1H NMR was the same as previously 
described97.   
 
2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl diphenyl 
phosphate (29).  A solution of alcohol 28 (0.162 g, 0.834 mmol), diphenyl phosphoryl 
azide (0.539 mL, 2.5 mmol) and DMF (6.7 mL) was cooled to 0 ⁰C in a water ice bath, and 
then treated with DBU (0.374 mL, 2.5 mmol).  The reaction mixture was allowed to 
warm to room temperature, stirred for 16 h, and then distributed between ethyl acetate 
and water. The combined organic extracts were washed with brine, dried over sodium 
sulfate, and concentrated to an off-white solid.  Trituration in ethyl acetate with a small 
amount of methanol gave 0.350 g (98 %) of the product as a white solid.  Rf 0.76 (4:1, 
ethyl acetate: methanol); 1H NMR (DMSO-d6) 10.80 (br s, 1H), 10.25 (br s, 1H), 7.39 (t, J 
= 7.7, 3H), 7.24 (t, J = 7.7, 2H), 7.17 (d, J = 7.7, 3H), 6.46 (s, 1H), 6.04 (br s, 2H), 4.52 (q, J 
= 6.8, 2H), 2.96 (t, J = 6.8 , 2H); MS m/z 449.0 (M+Na)+, 875.0 (2M+Na)+. 
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2-Amino-5-(2-azidoethyl)-3H-pyrrolo[2,3-d]pyrimidin-4(7H)-one (19).  A mixture of 29 
(0.186 g, 0.436 mmol), sodium azide (0.142 g, 2.181 mmol), tetra-n-butylammonium 
iodide (0.016 g, 0.044 mmol), 15-crown-5 ether (10 µL, 0.044 mmol)  and  DMA (3.5 mL) 
was stirred at 80 °C for 18 h.  The reaction mixture was concentrated in vacuo to give a 
brown solid that was dissolved in methanol and prepared for dry loading onto a 
chromatography column.  The product was purified by SiO2 chromatography (ethyl 
acetate to 4:1 mixture of ethyl acetate: methanol, gradient).  Product fractions were 
pooled and concentrated in vacuo to give the product (0.060 g, 61 %) as a yellow-white 
powder.  Rf 0.63 (4:1, ethyl acetate: methanol); 
1H NMR (DMSO-d6) δ 10.77 (br s, 1H), 
10.22 (br s, 1H), 6.48 (s, 1H), 6.03 (s, 2H), 3.56 (t, J = 6.6, 2H), 2.82 (t, J = 6.6, 2H); 13C 
NMR (DMSO-d6) δ 159.69, 152.74, 151.99, 115.20, 114.52, 100.00, 51.53, 26.42; MS m/z 
220.1 (M+H)+; HRMS (ESI) m/z 220.0949 [(M+H)+; calcd for C8H10N7O
+:  220.0947 ]. 
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Chapter V 
Evaluation of Azide Probes 
Both azide probes were designed as analogues of preQ1, the precursor of 
queuine that eubacteria incorporate into RNA with TGT before elaboration to queuine, 
with the intent they would be substrates.  The basis for this came from previous work in 
the Garcia lab42a and others41, which had demonstrated that TGT could accept alternate 
molecules as substrates that shared the pyrrolopyrmidine core.  The work of Romier20 
and our own work3 demonstrated, through comparative kinetic studies of the TGT 
enzymes with radio-labeled substrates, that the eukaryal and eubacterial TGTs had 
evolved from a common ancestor to accommodate their respective substrates.  These 
studies indicated TGT was amenable to changes of the side chain, provided the core 
pyrrolopyrimidine remained. 
Our interest in preparing azide probes originated from the knowledge that 
queuine modification occurs across eukaryotes and eubacteria with few exceptions, but 
its function remains unclear.  In addition, it had been observed that preQ1 could be 
incorporated into alternate RNA species in vitro other than the four identified tRNAs.  
The azide probes, if substrates, would provide a means to identify other species of RNA 
that are substrates for queuine modification.  As azides have been demonstrated to be 
bioorthogonal, after incorporation into RNA they can be subjected to Staudinger ligation 
or click chemistry conditions to be linked to a biotin-tethered reagent for subsequent 
isolation and concentration90a, b, 90e.  Therefore, we would be able to utilize the unique 
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method of queuine modification, transglycosylation, as a point of entry to study queuine 
prevalence more specifically.  The azide probes also have the potential to allow for sites 
of modification within the substrate RNAs to be identified. 
 The first aspect of studying the two azide probes was to determine their 
apparent Ki against TGT in order to establish if they interact with TGT.  The apparent Ki 
value can guide future experimental design, indicating appropriate concentrations for 
evaluation of the azides’ incorporation.  The kinetics of a competitive substrate and 
competitive inhibitor are identical in kinetic analysis with our experimental design, so a 
Ki apparent would be identical to the Km if the azides were indeed alternate substrates.  
The azide probes were initially tested with E. coli TGT in a guanine exchange assay at 
various concentrations ranging from a control with no azide to 1 mM concentration of 
the azide in a “decade search”.  This information was then used to determine an 
appropriate range of inhibitor concentrations to more precisely determine the Ki of each 
probe as had been performed previously3, 94.  A range that was deemed appropriate for 
each was selected and those azide concentrations were tested against three different 
concentration of labeled substrate, [14C] guanine.  For azide probe 18 the following 
concentrations, as seen in Figure 5-1, were used:  5, 50, 100, 250, 500 µM.  The 
following concentrations of azide probe 19, as seen in Figure 5-2, were used for the 
guanine exchange assay:  10, 100, 175, 250, 500, 1000 µM.  We elected to perform the 
Dixon analyses with  three concentrations of guanine to confirm the competitive nature 
(competitive inhibitor or competitive substrate) of the azide interaction with TGT.. 
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Initial experiments with these concentrations of azide probes were examined 
with different [14C] guanine concentrations to determine conditions for analysis of the 
azide probes.  Ideally, a concentration below the Km of guanine, at Km and above Km 
would have been utilized, but this was not possible for our experiment.  It was 
determined that although the Km of guanine for TGT is 0.35 µM
3 that concentration or 
any lower concentration of guanine would not work since sufficient DPM counts would 
not be achieved to characterize the enzyme's interaction with the azides.  The lowest 
concentration examined that gave adequate DPM counts was 0.75 µM.  The labeled 
guanine substrate was next examined at 1.00 µM and 1.50 µM.  The values obtained by 
these two values were nearly identical and prompted concerns they were too close for 
differentiation and would lead to difficulty in analyzing the data.  Therefore, 5.00 µM 
was chosen as the third substrate concentration for the Ki determination of the azide 
probes. 
 Experiments to confirm the azide probes as substrates for TGT would be 
undertaken when the apparent Ki was determined.  With that value determined 
incorporation experiments could be designed and the resulting RNA analyzed for 
modification with the azide analogues of preQ1.  The confirmation experiments planned 
included mass spectrometry with the mini-hairpin of RNA and tRNATyr.  In addition, trials 
to work out conditions for the Staudinger ligation and click chemistry with a copper free 
click reagent would allow for an alternate means to test for incorporation and validate 
our design to pull down the resulting modified RNA.  The azide probes would be tested 
and monitored by HPLC at several time points with the reagents at various 
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concentrations of azide and reagent to determine conditions for the Staudinger ligation 
or click reaction.  Once the sample was tethered to the biotin of those reagents, it could 
be incubated in streptavidin coated wells, which would be subsequently tested for the 
presence of RNA with RiboGreen® fluorescent to confirm modification and ligation or 
click reaction with a respective reagent could be performed.  If validated as substrates 
for E. coli TGT, future studies to identify alternate sites of queuine modification could be 
conducted in vitro and in vivo based on the methods developed with the cell lines used 
in our previous work to determine the prevalence of the queuine modification with 
radio-labeled preQ1. 
 
Results and Discussion 
 Before starting the experiments to determine Ki, an inactivation study with azide 
probe 18 was carried out.  With the difficulty in generating certain probes as described 
in Chapter IV, the benzylic-like connection of azide 18 could cause it to act as an 
inactivator.  Therefore a set of experiments were performed, as had been described in 
previous work by Hoops94, to evaluate azide 18 as an inactivator.  Evaluation occurred at 
150 µM concentration of azide 18.  Pre-incubation times of 15 min, 30 min, 1h and 2h 
were used.  Each experiment was run in duplicate and compared to a control run 
simultaneously.  In every case, the control counts collected were identical to those 
obtained for reactions using pre-incubated enzyme, as seen in Table 5-1.  As azide 19 
had been designed and generated as a less reactive alternative to 18, it was not tested 
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in this manner.  The results indicated that the azide probes were not inactivators and 
experiments to determine the Ki commenced.  
 
 
Table 5-1:  Pre-incubation with azide 18.  Azide data compared to control, pre-
incubation preformed with 150 µM of azide 18, 5 µM TGT and tRNA at 20 µM.  Data 
presented is average of two experiments. 
 
 
Once the DPM data was obtained from the guanine exchange assays by liquid 
scintillation counting, the data was converted into pmol of guanine using its specific 
activity (46.4 mCi/mmol).  The pmol of guanine were then plotted versus time, as seen 
for azide probes 18 and 19 as shown in Figure 5-1 and 5-2 respectively, to determine the 
rate of incorporation.  The rate and the concentrations were used to construct Dixon 
plots103 that are presented in Figure 5-3.  In a Dixon plot if the molecule under 
investigation is a competitive inhibitor (or models as such), the lines for data where 
substrate concentration is held constant should intersect in the second quadrant at –Ki.  
If the interaction is non-competitive they should intersect at the x-axis between the 
second and third quadrant.  If the lines do not intersect at one of these locations, the 
interpretation is that a more complicated binding relationship is occurring. In 
 15 min 30 min 1 h 2h 
minutes Azide 
18 
Control Azide 
18 
Control Azide 
18 
Control Azide 
18 
Control 
2 20.18 23.96 26.85 19.96 26.13 18.83 27.19 26.83 
4 39.04 40.67 34.29 33.14 34.40 31.96 40.61 41.02 
8 55.03 59.36 47.55 47.08 63.77 61.05 74.13 70.16 
16 70.93 73.94 64.47 64.66 112.77 106.90 137.41 124.55 
32 85.90 89.16 72.44 73.53 203.05 181.97 216.23 216.72 
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constructing the Dixon plots, the reactions with the highest concentration for each azide 
probe were removed from the analysis as the most error is associated with those data 
points.  The Ki of each could be estimated from the plots, but the analysis did not give 
the expected data pattern. 
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Figure 5-1:  Inhibition of guanine incorporation by azide probe 18. Trials were run with 
the following conditions: 0.1 μM TGT; 10 μM tRNATyr; 0.75 μM, 1.50 μM, or 5.00 μM 14C 
guanine.  Experiments were performed in duplicate.  Data was obtained by quenching 
and precipitating 70 μL of reaction mixture in 5 % TCA, and the resulting precipitate was 
collected by filtration.  Liquid scintillation counting provided raw data for analysis. 
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Figure 5-2:  Inhibition of guanine incorporation by azide probe 19.  Trials were run with 
the following conditions: 0.1 μM TGT; 10 μM tRNATyr; 0.75 μM, 1.50 μM, or 5.00 μM 14C 
guanine.  Experiments were performed in duplicate.  Data was obtained by quenching 
and precipitating 70 μL of reaction mixture in 5 % TCA, and the resulting precipitate was 
collected by filtration.  Liquid scintillation counting provided raw data for analysis. 
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Figure 5-3:  Dixon plots for each azide probe; based on guanine exchange assay data. 
 The first unexpected pattern in the data occurred in the guanine exchange assay 
charts.  While the data fit would be expected to curve over time, it was not expected 
that enough reaction progress would be made for the data in our reaction design to go 
beyond the linear range, but the data clearly curves.  Based on the pmol incorporated at 
the final time point, an estimate of the percent completion can be calculated to 
y = 0.9791x - 13.155 
R² = 0.9057 
y = 0.178x + 12.097 
R² = 0.9219 
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determine if the reaction had gone beyond the linear region of the conditions.  It was 
determined that by the final time point of the reaction that approximately 20 % of the 
labeled guanine had been incorporated in the reactions, which would explain the loss of 
linearity of the data as the substrate concentration was dropping significantly..  
Therefore, to fit the data to determine the initial rate of reaction the final time point 
was excluded. 
  The patterns generated by the three line fits in the Dixon plots were also not as 
expected.  The lines for a competitive inhibitor or substrate would be expected to 
intersect in the second quadrant.  This is not the case for our azides.  The three fits do 
not arrive at the same value and give an intercept in first quadrant or on the y-axis, 
which indicates that the azides are likely displaying mixed inhibition.  The data pattern 
could also be the result of a different, additional binding mode being present at higher 
concentrations of the azides or for the substrate.  If the elevated levels lead to binding 
to the free enzyme as well as the enzyme-tRNAtyr complex, a more complicated pattern 
would arise.  To fully characterize the azides, further experimentation would be 
required; however, our primary interest in performing the experiments had been to 
determine a concentration to run the subsequent incorporation studies to validate the 
azides as substrates.  From the data we determined, using the equation in Figure 5-4, 
that the Ki for each azide is approximately 70 µM, which is greater than that for guanine, 
0.35 µM, or its natural substrate preQ1, 0.05 µM
3.  Observing the expected pattern for a 
competitive inhibitor or substrate was desired, but obtaining an apparent Ki value for 
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subsequent experiments allowed us to continue our evaluation of the azide probes as 
alternate substrates. 
vSK
K
K
cat
m
i
][
  
Figure 5-4:  Equation used to calculate the Ki of a competitive inhibitor or substrate; 
rates determined in the Dixon plots, Km of guanine with TGT is 0.35 µM, Kcat is 0.00629 
µM. 
 
 In order to determine if the azides are substrates for TGT, experiments were 
designed to modify and isolate RNA post treatment with TGT and an azide probe.  The 
azide probes at 200 µM (approximately 3x Ki apparent) were incubated overnight with 
RNA and TGT was added every 6 h.  Two RNAs were used.  First, a mini-hairpin of the 
tRNAtyr was used as had been utilized in earlier work to demonstrate preQ1 
incorporation by mass spectrometry38.  Later, full length tRNAtyr was utilized under the 
same conditions.  A representation of the experiments is presented in Figure 5-5.  The 
reactions were quenched by ethanol precipitation and the samples were desalted and 
submitted for mass spectrometry analysis, utilizing electron spray ionization.  In neither 
analysis with either RNA substrate was the incorporation of the azide observed; intact 
mass of starting RNA was observed instead.  The mass spectrometry analysis of an 
untreated sample of mini-hairpin and tRNA was performed concurrently.  The small 
mass change made detection difficult for experiments with full length tRNA, so 
attempting the ligation with the Staudinger ligation reagent to make the mass 
difference between product and starting tRNA greater was attempted.  Only mass to 
charge values smaller than the starting tRNA was observed, demonstrating a breakdown 
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of the tRNA likely due to the incubation for the ligation reaction and extra handling of 
the tRNA.  These experiments failed to show that the azide probes were substrates for 
TGT, but as questions remained about using mass spectrometry to verify incorporation 
(a low percentage of RNA modification might not be detected) another set of 
experiments were undertaken to examine if the azide probes were substrates for TGT. 
 
Figure 5-5:  Test of azide analogues of preQ1 as substrates for TGT.  Prepared tRNA
Tyr 
was used as well as 25 base stem loop for analysis by mass spectrometry.  Biotin-
strepavidin affinity experiments used prepared tRNATyr. 
 
 The final attempt to determine if the azides were substrates for TGT started with 
first testing the ligation and click reactions with each probe to ensure that the proper 
chemistry was occurring.  The azide probe and Staudinger ligation reagent were 
incubated at various concentrations and assayed by HPLC at various time intervals to 
monitor reaction progress.  It was determined that the Staudinger ligation reagent 
needed to be at a concentration of at least 2.5 µM for the reaction to proceed, and an 
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excess of ligation reagent was required for the reaction to go to completion, as 
observed by HPLC at 24 h.  It was also determined that the ligation reagent had to be 
dissolved in DMF as it is oxidized by DMSO and has inadequate solubility in H2O.  An 
alternative to the Staudinger ligation reagent was also examined.  A copper free click 
reagent, a dibenzylcyclooctyne with a PEG-4 linker to biotin from Jenna Bioscience 
(Figure 5-6), was also examined.  This reaction proceeded at lower concentrations (0.1 
µM) of reagent, could be run in 2 h, and would not be reactive with DMSO.  However, 
the reaction still required an excess of reagent to go to completion.  
 
 
Figure 5-6:  Dibenzylcyclooctyne-PEG4-Biotin Conjugate Reagent, Jenna Bioscience 
 
 With conditions for the Staudinger ligation and copper free click reaction worked 
out, the azide incorporation experiments were performed again with prepared tRNAtyr.  
The isolated tRNAtyr was subjected to the ligation or click reaction for 24 h before 
isolation of the RNA.  The RNA was then suspended in Milli-Q H2O and incubated in a 96 
well plate coated with strepavidin.  Each reagent is tethered to biotin, so any modified 
RNA would be bound to the plate through biotin’s interaction with strepavidin.  The 
wells were washed and analyzed for RNA concentration with RiboGreen® fluorescent 
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dye.  The wells with tRNA isolated from the ligation or click reaction gave values equal to 
negative control, unmodified tRNA.  Therefore, this set of experiments also failed to 
demonstrate that the azides are substrates for eubacterial TGT, although the possibility 
remains that they are substrate for human TGT or even eubacterial TGT under yet to be 
identified conditions. 
In conclusion, the azide probes interact with eubacterial TGT.  The type of 
interaction has yet to be determined, but analysis indicates that the apparent Ki of the 
interaction is approximately 70 µM.  The azide probes do react with the Staudinger 
ligation probe and copper free click reagent.  Alternate methods to observe the 
incorporation might be more successful or conditions described here could be optimized 
for detection of the modified species.  Evaluation with the human version of TGT with its 
larger binding pocket that accommodates queuine could prove more successful with the 
presented methods.  Work with the human form of the enzyme is desirable and should 
be the focus in the future given the yet to be understood nature of queuine’s role in 
cancer progression. 
 
Experimental Procedures: 
TGT [14C] guanine exchange assay of azide probe 18. Assays were performed with azide 
probe 18 under the following conditions: 0.1 μM TGT; 10 μM tRNAtyr; 0.75 μM, 1.50 μM, 
or 5.00 μM 14C Guanine at six concentrations of azide probe 18: control (no azide), 5, 50, 
100, 250, 500 µM.  Experiments were performed in duplicate in bicine buffer.  Data was 
obtained at time points for 2, 4, 6, 8, 10 min by quenching and precipitating 70 μL of 
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reaction mixture in 5 % TCA.  The resulting precipitate was collected by filtration.  Liquid 
scintillation counting provided raw data for analysis. 
TGT [14C] guanine exchange assay of azide probe 19. Assays were performed with azide 
probe 19 under the following conditions: 0.1 μM TGT; 10 μM tyr tRNA; 0.75 μM, 1.50 
μM, or 5.00 μM 14C Guanine at six concentrations of azide probe 18: 10, 100, 175, 250, 
500, 1000 µM.  Experiments were performed in duplicate in bicine buffer.  Data was 
obtained at time points for 2, 4, 6, 8, 10 min by quenching and precipitating 70 μL of 
reaction mixture in 5 % TCA.  The resulting precipitate was collected by filtration.  Liquid 
scintillation counting provided raw data for analysis. 
 
Pre-incubation study of azide 18 with TGT [14C] guanine exchange assay. Azide 18 at 
150 µM was incubated with 5 µM TGT in the prescence of tRNA at 20 µM in bicine 
buffer for 15, 30, 60, 120 min.   A control pre-incubation of TGT without any of azide 18 
was also performed.  Following incubation, TGT was diluted into a [14C] guanine 
exchange assay with the following conditions in a bicine buffer:  20 µM tyr tRNA, 0.1 µM 
TGT (from pre-incubation), 20 µM [14C] guanine.   Experiments were run in duplicate and 
time points were taken at 2, 4, 6, 8, 10 min.    
 
Azide incorporation into tyrosine tRNA. TGT mediated incorporation of azide probes 18 
and 19 was attempted with the following conditions:  tyr tRNA 80 µM, azide probe 200 
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µM, TGT 1.4 µM in bicine buffer.  An additional aliquot of TGT was added at 6 h and 12 
h, and the reaction was quenched by ethanol precipitation at 18 h.  The resulting tRNA 
was pelleted by centrifugation at 13k rpm for 10 min in a table top eppendorf 
centrifuge.  The pellet was washed twice with 70 % ethanol and air dried 10 min before 
being suspended in solvent for subsequent use.  
 
Staudinger Ligation of azide probe 18. Ligation reaction of azide probe 19 was 
examined in carbonate-bicarbonate buffer at a pH of 9.0 in a 1:10 ratio of azide to 
Staudinger ligation reagent 31.  The Staudinger ligation reagent 31 was suspended in 
DMF at a concentration of 5 mM for a stock solution.  The reaction was attempted at 
the following concentrations of azide probe: 0.1, 1.0 and 2.5 mM.  The progress of the 
reaction was monitored by HPLC at 1h, 2h, 4 h, 18 h, 24 h.  HPLC experiments were run 
as a gradient from 10% to 90 % of acetonitrile (0.1 % TFA) with water (0.1 % TFA) over 
10 minutes.  
 
Copper free click reaction of azide probes. Click reaction of azide probe 18 and 19 was 
examined in carbonate-bicarbonate buffer at a pH of 9.0 in a 1:1, 1:10, 1:50 ratios of 
click reagent with respective azide being analyzed.  The click reagent from Jenna 
Bioscience was suspended in DMSO to give a 6.67 mM stock solution. The reaction was 
attempted at the following a concentration of azide probe of 1.0 mM and monitored by 
HPLC at 1h, 2h, 4 h, 18 h, 24 h.  HPLC experiments were run as a gradient from 10% to 
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90 % of acetonitrile (0.1 % TFA) with water (0.1 % TFA) over 10 minutes.  The progress of 
the reaction was monitored by HPLC at 1h, 2h, 24 h.  HPLC experiments were run as a 
gradient from 10% to 90 % of acetonitrile (0.1 % TFA) with water (0.1 % TFA) over 10 
minutes. 
 
Mass spectrometry sample preparation. Samples of mini-hairpin RNA and tyrosine 
tRNA were purified by one of two methods.  The first method utilized was to ethanol 
precipitate the sample with a 10 % volume to volume addition of 5M NH4OAc at pH 5.3 
and then 250 % addition of ethanol.  Samples were stored at -20 °C for 8 h.  Precipitated 
RNA was pelleted by centrifugation at 13,000 rpm for 10 min in a table top eppendorf 
centrifuge.  The pellet was washed twice with 70 % ethanol and air dried 10 min before 
being suspended in H2O.  The process was repeated twice before the sample was 
submitted for analysis.   
The alternate method was to use a Millipore™ Zip-Tip® C18 resin to desalt the 
sample.  The Zip-Tip® was attached to a 10 µL pipetman and washed twice with 10 µL of 
a wetting solution consisting of a 1:1 ratio of acetonitrile to Milli-Q H2O.  The tip was 
then equilibrated by washing three times with 10 µL of a 0.1 M triethyl ammonium 
acetate at pH 7.0 solution.  The sample of RNA in solution was purified by adhering RNA 
to the resin by taking up 10 µL of the sample into the tip followed by aspirating the 
sample and repeating the procedure ten times.  The sample on the resin was then 
washed with 10 µL of a 0.1 M triethyl ammonium acetate at pH 7.0 solution three times.  
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The sample was then washed with 10 µL Milli-Q H2O three times.  To elute the sample 
for analysis, 10 µL of a 1:1 ratio of acetonitrile to Milli-Q H2O was added to a eppendorf 
tube.  The solution was taken into the Zip-Tip® and aspirated and the cycle repeated 10 
times. 
 
Azide probe modified tRNA with Staudinger ligation reagent. After allowing an azide 
probe to interact with TGT and tyrosine tRNA as described previously, the pelleted 
sample was suspended in carbonate-bicarbonate buffer at a pH of 9.0 to a volume of 20 
µL.  Ligation stock solution (DMF) was added to give a final concentration of 2.5 mM of 
reagent.  The reaction was run at room temperature for 24 h until quenched by ethanol 
precipitation.   
 
Azide probe modified tRNA with click reagent. After allowing an azide probe to interact 
with TGT and tyrosine tRNA as described previously, the pelleted sample was suspended 
in carbonate-bicarbonate buffer at a pH of 9.0 to a volume of 100 µL.  Click reagent 
stock solution (DMSO) added to give a final concentration of 2.5 mM of reagent.  The 
reaction was run at room temperature for 24 h until quenched by ethanol precipitation.   
 
Biotin streptavidin affinity analysis of azide probes with Ribogreen®. A 96 well black 
flat bottom streptavidin coated plat was washed three times with TE buffer (pH 7.5).  
The RNA solution was resuspended in 150 µL TE buffer and added to a well of the 96 
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well plate.  In addition, 150 µL of unmodified tyrosine tRNA, at the same concentration 
(determined by nanodrop) was added to a well to serve as a control.  The plate was 
incubated at 37 °C for 30 min.  The sample was removed and the plates washed three 
times with TE buffer.  The samples were suspended in 75 µL of TE buffer and 75 µL of 
Ribogreen fluorescent dye, working stock prepared by vendor’s protocol, was added.  In 
addition, tyrosine tRNA at five known concentrations was added to another lane of wells 
with ribogreen dye to serve as a standard curve: 0.16, 0.32, 0.64, 1.28, 2.56 ng/µL of 
RNA (determined by nanodrop).  
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Chapter VI 
Conclusions 
 In the course of completing this dissertation project many of the objectives set at 
the start were completed.  The proposed target molecules for the project were all 
generated.  In doing so, we developed a concise, convergent synthesis of queuine that is 
the shortest route developed to date.  Our route features a short high yielding synthesis 
of a key intermediate, aldehyde 5, which allowed for the facile synthesis of preQ1 and 
queuine.  This aldehyde could also be used as an intermediate for generating many 
other yet-to-be synthesized pyrrolopyrimidine analogues.  The designed route also 
worked as planned in allowing for the straightforward generation of tritium-labeled 
versions of queuine and preQ1.  Having those labeled substrates has allowed the lab to 
study the kinetics of TGT directly and has provided a means to examine the differences 
between eukaryal and eubacterial TGT.  Our route to the aldehyde 5 also demonstrated 
the use of silyation to enhance reactant organic solubility, which allowed for the 
straightforward reduction of a heterocyclic nitrile with DIBAL-H that was otherwise 
difficult to achieve. 
 In addition to generating unlabeled and labeled versions of the substrates for 
eubacterial and eukaryal TGT, we also completed the synthesis of two novel azide 
congeners of preQ1.  We demonstrated the utility of diphenylphosphoryl azide for 
installing azides by substitution of both a benzylic like alcohol (giving azide 18), as well 
as an alkyl alcohol to give azide probe 19.  The means of generating a stable salt form of 
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chloro(formyl)acetonitrile provides an improvement in the synthesis of 
pyrrolopyrimidines.  Even though limited attempts at condensations of related 
heterocyclic substrates with it suggests that the reagent may have precise reactivity 
requirements, further reaction conditions need to be examined to determine if it has 
broader utility.   
Our biological experiments with the target molecules also presented us with 
interesting findings.  The use of radio-labeled preQ1 allowed us to confirm several 
previous observations.  First, we confirmed that RNA other than tRNA can be modified 
in vitro by TGT.  The in vivo work with TG2 and ΔqueC cell lines verified previous 
experiments examining the preQ1 riboswitch.  The work demonstrated that exogenously 
supplied preQ1 can enter the cell.  In addition, we observed in vivo a high level of [
3H] 
preQ1 incorporation into the RNA of the TG2 cells, consistent with prior findings that 
preQ1 will bind to the riboswitch and halt biosynthesis of preQ1, resulting in the bacteria 
utilizing the provided preQ1.  It was also demonstrated that the four known tRNAs are 
the main site of incorporation in vivo.  Our experiments did not rule out other naturally 
occurring sites of queuine modification, but they did demonstrate that the vast majority 
of the modification occurs in tRNA with any other modification occurring either in low 
abundancy species of RNA or being the result of a regulated means of access to the 
modifying enzyme affording only a small percentage to be modified. 
 The designed azide probes did work in Staudinger ligation and copper free click 
reactions and at least act as competitive inhibitors of guanine exchange by the E. coli 
TGT, but it was not determined if they are TGT substrates.  More analysis is likely 
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required and experiments with the human version of the enzyme may work more easily 
given the increased size of the binding pocket.  A study of queuine modification sites in 
human tissue would also be of greater interest, given the correlation of queuine levels 
and cancer progression described in the literature.  This work has also presented some 
ideas for alternate experiments that merit further study. 
 As described in the appendix to chapter V, aldehyde 5 has the potential to be an 
interesting inhibitor of TGT given its structure seems perfectly suited to bind in the 
active site of TGT.  It also would seem to have a built in preference for the eubacterial 
TGT given it contains a cysteine residue the eukaryal form lacks that normally interacts 
with the amine of preQ1
3.  That cysteine residue is where the aldehyde would be located 
if its binding is directed by the pyrrolopyrimidine core, which would create a selectivity 
that could prove interesting in TGT studies.  In addition, our ability to synthesize 
queuine and preQ1 also allows for some new experiments to study the redundant codon 
bias theory long postulated and supported by some data.  With the ability to prepare 
our own tRNA and modify it ourselves with prepared queuine and TGT, one could 
imagine a single molecule experiment with alternate mRNA that would allow for a 
binding study like that recently performed by the Cornish lab104 to determine if amino 
acids required their respective tRNA for binding to the ribosome.  A study with mRNA 
biased in varying degree for U ending and C ending codons could allow for such a study.  
The study would be more direct and controlled than the experiment run in the 1970s by 
Nishmura and Harada4. 
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 One other study that comes to mind based on this work would be to generate 
the 15N labeled version of azide probe 19.  That would allow for a means to follow its 
incorporation by NMR.  In addition, if it were a substrate it would provide a means for 
ligation or click reaction and could also be used for NMR studies of the affected RNA.  
Generating the 15N labeled azide probe 18 would provide a direct means to a labeled 
preQ1 Staudinger reduction, which could be utilized in preQ1 riboswitch experiments to 
further elucidate the function and mechanism of the binding domain.  While generating 
15N labeled 19 would be straightforward as it utilizes sodium azide as the source of the 
azide, the situation for 18 is more complicated.  It is likely that the DPPA reagent 
functions through a substitution in which azide is released to form the phosphoryl 
intermediate of the hydroxyl, in which case addition of labeled sodium azide would 
allow for partial incorporation of the 15N label.  This reaction would also help validate 
the reaction mechanism and determine whether or not the conversion to the azide is 
concerted or stepwise. 
 This project has accomplished many of its objectives and has created the 
opportunity for alternate projects through the molecules generated as part of the study. 
The prevalence of queuine is still not fully elucidated, but the picture is becoming 
clearer.  The in vitro modifications observed by us and others do not correlate to 
widespread prevalence in vivo, which presents some interesting questions as to how the 
enzyme responsible for the modification is controlled.  In addition, our work has served 
to support some previously held ideas, e.g. that preQ1 is absorbed and used as a 
nutrient.  Also, we have verified some previous findings with our in vivo studies, i.e. the 
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preQ1 riboswitch will halt synthesis of preQ1 and use the provided preQ1.  While my 
work did not achieve every goal set forth at the beginning of my research, we remain 
optimistic that many of these can still be achieved, chiefly incorporation of the azide 
probes.  In summary, we have gained a better understanding of queuine modification of 
RNAs and have developed tools that will aide in future studies. 
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Appendix I 
Spectral and Other Characterization Data for Chapter II and IV 
This appendix consists of characterization data for molecules not synthesized 
previous to this dissertation work and all final products.  The NMR spectra were 
recorded on a Bruker DRX instrument at 500 MHz for 1H and 125 MHz for 13C spectra.  
Chemical shift values are recorded in  units (ppm).  Mass spectra were recorded on a 
Micromass TofSpec-2E Matrix-Assisted, Laser-Desorption, Time-of-Flight Mass 
Spectrometer in positive ESI mode.  Characterization data for tritium labeled 
compounds was performed by Moravek as described on provided data sheets.  
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Appendix II 
Chapter V, Kinetic Evaluation of Aldehyde 6 
 
Preliminary evaluation of aldehyde 6 as an inhibitor of E. coli TGT was 
performed.  In addition, to the azide probes, aldehyde 6 was also examined as an 
inhibitor or inactivator of TGT.  In trying to generate the halogen analogues of preQ1 and 
in our synthesis of aldehyde 6 we came to realize that it was likely that Hoops had 
generated a C-6 regioisomer of the aldehyde 6 (see Chapter II for synthesis) and the 
fluoride (attempted synthesis described in Chapter IV) analogue.  This possibility arose 
when we found we could not generate our desired fluoro analogue, and that the NMR 
line listing for the aldehyde Hoops reported did not match that for aldehyde 6.  We had 
not considered testing aldehyde 6 as Hoops had reported biological data earlier on his 
compound42a.  But becoming aware that Hoops’ and our own aldehydes were not the 
same suggested that a reexamination was warranted.  Given the binding pocket of TGT, 
the aldehyde analogue of preQ1 could represent an excellent inhibitor if stable.  In 
addition, the difference in eubacterial and eukaryotic TGT, particularly the cysteine 
residue that interacts with the preQ1 primary amine that is not present in the eukaryotic 
version, might represent a cause for a selectivity difference between the two forms of 
the enzyme.   
 First, a “decade search” (e.g., inhibition experiments with the aldehyde at a 
series of ten-fold concentration dilutions) was performed to find the appropriate 
concentration range for the aldehyde in subsequent experiments.  The data from that 
171 
 
experiment is shown in Figure 5-5.  The reactions at a concentration of aldehyde 6 at or 
below 0.1 µM are identical to the no inhibitor control.  The reaction at 1 µM shows a 
decrease in incorporation of labeled guanine.  The reaction at 100 µM shows a complete 
inhibition of guanine incorporation.  This is inconsistent with the data Hoops 
reported42b.  This data warranted further investigation of the aldehyde.  Given that the 
aldehyde can readably react with amines, as determined in our synthesis of queuine and 
preQ1 as well as those of others, the aldehyde could be an inactivator. 
 
 
Figure II-1:  Preliminary evaluation of aldehyde 6 at substrate concentration of 1.5 µM 
at 5 concentrations with a control. 
 
 An inactivation study with aldehyde 6 was run with concentration of aldehyde in 
the pre-incubation at 200 µM, as seen in Figure 5-6.  In, all the pre-incubation intervals 
the similar curves were observed, which demonstrated a decrease in activity when 
compared to control reactions although not as expected for inactivation.  It would be 
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expected for the rate to decrease for longer pre-incubation times if the molecule were 
an inactivator.  At a starting concentration of 200 µM for the pre-incubation, a 
concentration of 4 µM would still be present when the TGT was added.  This indicates 
that what is being seen could be the result of competitive inhibition and not inactivation 
of TGT.  This analysis is preliminary and more experiments at different concentrations of 
aldehyde 6 and substrate should b performed before any conclusions are drawn.  It is 
likely that the aldehyde 6 could be a competitive substrate, which would yield identical 
kinetics to those for a competitive inhibitor.  Further experiments should be conducted 
to determine the apparent Ki (possibly Km) of aldehyde 6 and its mode of interaction 
with the enzyme, as it could be an important probe to study differences between 
eubacterial and eukaryotic TGT.  This work fell outside the focus of my project and was 
not pursued further due to time constraints. 
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Figure II-2:  Inactivation study of aldehyde 6; incubated with 200 µM of azide with 5 µM 
TGT in the presence of tRNA at 20 µM; guanine exchange assays, 1.5 µM guanine, 
initiated with enzyme from pre-incubation at 15 min, 1 h and 2 h; Control reaction from 
alternate day, same conditions utilized. 
 
TGT [14C] guanine exchange assay of aldehyde 6. Assays were performed with aldehyde 
6 under the following conditions: 0.1 μM TGT; 10 μM tRNATyr; 1.50 μM 14C guanine at six 
concentrations of aldehyde 6: control (no aldehyde 6), 0.01, 0.1, 1.0, 10, 100 µM.  
Experiments were performed in duplicate in bicine buffer.  Data was obtained at time 
points for 2, 4, 6, 8, 10 min by quenching and precipitating 70 μL of reaction mixture in 5 
% TCA.  The resulting precipitate was collected by filtration.  Liquid scintillation counting 
provided raw data for analysis. 
 
Pre-incubation study of aldehyde 6 with TGT [14C] guanine exchange assay. Aldehyde 6 
at 200 µM was incubated with 5 µM TGT in the presence of tRNA at 20 µM in bicine 
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buffer for 15, 30, 60, 120 min.   A control pre-incubation of TGT without any of aldehyde 
6 was also performed.  Following incubation, TGT was diluted into a [14C] guanine 
exchange assay with the following conditions in a bicine buffer:  20 µM tRNAtyr, 0.1 µM 
TGT (from pre-incubation), 1.5 µM [14C] guanine.   Experiments were run in duplicate 
and time points were taken at 2, 4, 6, 8, 10 min.    
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